Podcasts about biontech se

JCO PO author Dr. Philip Philip at Henry Ford Cancer Institute and Wayne State University shares insights into his JCO PO article, “Incorporating Circulating Tumor DNA Testing Into Clinical Trials: A Position Paper by the National Cancer Institute GI Oncology Circulating Tumor DNA Working Group.” Host Dr. Rafeh Naqash and Dr. Philip discuss how prospective trials are required to clarify the role of ctDNA as a valid surrogate end point for progression-free or overall survival in GI cancers. Transcript Dr. Rafeh Naqash: Hello and welcome to JCO Precision Oncology Conversations, where we bring you engaging conversations with authors of clinically relevant and highly significant JCO PO articles. I'm your host, Dr. Rafeh Naqash, Podcast Editor for JCO Precision Oncology and Assistant Professor at the OU Health Stephenson Cancer Center at the University of Oklahoma. Today, we are excited to be joined by Dr. Philip Philip, Chair of Hematology and Oncology, as well as leader of GI and Neuroendocrine Oncology. He's also the Professor of Oncology and Pharmacology, as well as Co-Leader of the Pancreatic Cancer Program and Medical Director of the Cancer Clinical Trial and Translational Research Office at the Henry Ford Cancer Institute at Wayne State University. Dr. Philip is also the Senior Corresponding Author of the JCO Precision Oncology article entitled, "Incorporating Circulating Tumor DNA Testing into Clinical Trials: A Position Paper by the National Cancer Institute GI Oncology Circulating Tumor DNA Working Group." At the time of this recording, our guest's disclosures will be linked in the transcript. Dr. Philip, welcome to our podcast, and thank you so much for joining us today. Dr. Philip Philip: Thank you so much, Dr. Naqash, for providing me this opportunity to be discussing this with you. Dr. Rafeh Naqash: This is a very timely and interesting topic. We've done a couple of podcasts on ctDNA before, but none that is an opinion piece or a guidance piece based on what you guys have done. Could you tell us what led to this perspective piece or guidance manuscript being published? There is some background to this. Could you tell us, for the sake of our listeners, what was the initial thought process of why you all wanted to do this? Dr. Philip Philip: The major reason for this was the fact that investigators were considering using ctDNA as a primary endpoint in clinical trials. Obviously, you hear my focus will be on gastrointestinal cancers. So, the idea was, can we use ctDNA instead of using the traditional endpoints such as disease-free survival, progression-free survival, or overall survival? And the question was, do we have enough data to support that in patients with gastrointestinal cancers? Now, the article obviously goes over some review of the data available, but the core of the article was not to do a comprehensive review of ctDNA use and the evidence so far, although we used that in really putting our recommendations. So, we really had to evaluate available data. But the focus was, what are the gaps? What do we need to do? And are we ready to use ctDNA as a primary endpoint in clinical trials? Dr. Rafeh Naqash: Thank you for giving us that background. Obviously, a very broad, complicated topic with a bunch of emerging data that you've highlighted. But most importantly, for the sake of, again, trainees and listeners, could you help us understand the difference between tumor-informed and non-tumor-based ctDNA assessments? Dr. Philip Philip: Sure. So, the tumor-informed is simply meaning that you're taking the genomic makeup or the DNA fingerprint of the cancer in a given patient, and you create a profile, and then use that profile to see whether that DNA is present in the blood. So, it's very simple. It's like barcoding DNA and then going and looking for it in the blood, which means that you have to have the primary tumor. When I say primary tumor, you need to have the tumor to start off with. It doesn't really apply, maybe easily, if you just have a fine-needle aspirate and things like that. So, you really have to have a good amount of the tumor for you to be able to do that. So, that's a tumor-informed, and from the name, you can easily understand how it's done, compared to the other one, which is uninformed, whereby off-the-shelf probes are used to look for tumor DNA. And again, they're based on prior experience and prior identification of the key DNA changes that will be seen in tumors. So, that's the difference between the two in terms of the principle of the test. The uninformed will not require you to send the original tumor that you're trying to test. However, the informed, you do. The turnaround time is, again, a bit different because, as you would expect, it's shorter in the uninformed. And the reason for that, again, is the initial preparation of the profile that is going to be used in the future when you do serial testing. The sensitivity has been a bit of a discussion. Initially, people have thought that tumor-informed assays are more sensitive, more specific, more sensitive, et cetera. But in our review, we come to the conclusion saying that we don't think that's going to be a major difference. And there are obviously improvements happening in both types of assays. The sensitivities have been improving. So, at this point in time, we do feel that you have two types of assays, and we didn't feel strongly about recommending one over the other. Dr. Rafeh Naqash: Thank you for that description. You mentioned something about sensitivity, specificity. Obviously, many of us who have ordered both tumor-informed and tumor-uninformed, we understand the differences with respect to the timing. The tumor-informed one can take more time. The uninformed one, being a sort of a liquid biopsy, may not necessarily have as much of a turnaround time. Could you briefly speak to those limitations or advantages in the context of the two versions? Dr. Philip Philip: I just really want to also highlight that when we say turnaround time, so for the tumor-informed assays, the first assay that we do will be requiring a turnaround time. But once the pattern has been set and the profile has been documented, the subsequent testing doesn't require much in the way of waiting. However, when you're using this for the minimal residual disease, then you have a window of opportunity to work at. That's number one. So, it means that in patients who have resected cancer, you may end up having to wait longer than the tumor-uninformed assay, especially if you don't have easy access to your material for the baseline material to send. And also, what we'd like to do is not do the test immediately after the operation or soon after the operation. Give it some time. There's a window where you can work at, and starting minimally two weeks after the surgery. But in my experience, I'd like to wait at least four weeks just to make sure that we got an accurate reading. Sometimes when you do it very early after surgery, because of the effect of the surgery and the release of the normal DNA is also, it may dilute the tumor DNA, and then you may get a false negative. So, basically, it depends on the clinical situation. And your question is, is one better to be used than the other? I think ultimately, it ends up with the turnaround time not being as much of an issue. It might be in certain situations, depending on when you see the patients after the operation or any definitive treatment you've done and you want to look for minimal residual disease. But in general, I don't think that's going to be a real major issue. Dr. Rafeh Naqash: I remember discussing this with one of the tumor-informed platforms with regards to this barcode you mentioned. They generate a fingerprint of sorts for the tumor on the tissue, then they map it out in the blood and try to assess it longitudinally. And one of the questions and discussions we had was around the fact that most of the time, these barcoded genes are not the driver genes. If you have a KRAS mutant tumor, it's not going to be the KRAS gene that they map out. It's something that is specific. So, is there a possibility that when you are mapping out, let's say, a metastatic tumor where there is truncal and subclonal mutations at different sites, that you capture something that is not necessarily truncal, and that does not necessarily reflect some other metastatic site having a recurrence? So basically, over time, you don't see a specific mutational pattern or the signature on the tumor-informed, and then you see something on the scan which makes you think, "Well, it was not the right test," but actually it could be a different subclone or a clone mutation at a different site. Is there a concept that could help us understand that better? Dr. Philip Philip: I think you raise a very important point. Although, I have to say from my practical experience, that is not a common thing to see. In fact, for some reason, we don't see it that often in any frequency that should, at this point in time, make us concerned about the serial testing. But what you were mentioning is a real challenge which can happen. Now, the question is, how often does the clonal evolution or the divergence happen to the point that it's going to be like a false negative, is what you're saying. At this point in time, we don't really have good information on that, or any good information, practical information. And when we went through the literature and we were looking for the evidence, that wasn't something which was there clearly telling us. Although, this is something that has to be studied further prospectively. And I don't know of a study, but I might be missing it, I don't know of a study which is systematically looking at this. Although it's a very valid hypothesis and theoretical basis for it, but in real life, we still have to see how much does it really interfere with the validity of this kind of testing. Dr. Rafeh Naqash: Which brings us to the more important discussion around your manuscript. And I think that the overarching theme here is the consensus panel that you guys had recommended that ctDNA-based metrics be used as a co-primary endpoint. Could you tell us, for early-phase trials, maybe phase two studies for that matter, could you tell us what were some of the aspects that led to this consensus being formed from your working group? Dr. Philip Philip: Well, there were a number of reasons, in any order of priority, but one of them is we don't have a good sense of dynamics of the ctDNA. And again, remember this article was about gastrointestinal cancers. Maybe we know more about colon cancer, but, or colorectal cancer, but we don't know that well about the upper GI, like gastroesophageal, pancreatic, et cetera. So, we don't know what is the false negative percentages. And in fact, we know that there are certain sites of the disease, metastases, that do not lead to enough shedding of the DNA into the circulation. So, that was something else. I mean, false negativity, not knowing exactly what the dynamics are, especially in different disease types. So, that was another reason, which we felt that it may not be at this time primetime to really have those ctDNA tests as a primary endpoint. We wanted to make sure that, on the other hand, we wanted to make sure that people consider including ctDNA more like a secondary endpoint so that we can gain the information that we're lacking, at least the ones I mentioned to you. So, that was an important point of our discussions and deliberations when we were writing the article. Dr. Rafeh Naqash: And I myself have been on both sides of the aisle where - I treat people with lung cancer, you mentioned appropriately that most of the data that we have for ctDNA is generated from GI cancers, especially colorectal - on the lung cancer side, I myself had a patient with an early-stage cancer, had treatment, surgery, immunotherapy, and then had ctDNA that was tumor-informed, was positive four to five months before the imaging actually showed up. And on the other side, I've also had an individual where early-stage lung cancer, surgery, immunotherapy, and then had PET scans that showed a positive finding, but the ctDNA, tumor-informed ctDNA, was negative multiple times. So, I've seen both aspects of it, and your paper tries to address some of these questions on how to approach a negative, radiologically negative imaging but positive ctDNA potentially, and vice versa. Could you elaborate upon that a little bit? Dr. Philip Philip: Well, obviously, we do see this in practice. Again, I do GI oncology. I have patients who, you do ctDNA. I mean, my advice to anyone, when you order a test, you have to make sure that you know what you're going to do with the test, because that's the most important thing. You get a positive test, you do something. You get a negative test, you do something. But most importantly, our patients who you're following up, they are very anxious for a diagnosis they have that is not- I mean, it's cancer. If you're doing these tests, if we get continuous, repeatedly negative testing, then you really have to also tell the patient that there's a false negativity. And I mentioned to you earlier, there are certain sites of disease, like peritoneal, they may not be producing enough, or there are some tumors, their biology is such that they don't release as much to be detected in the blood. Now, one day we will get maybe a more sensitive test, but I'm talking about the tests we have now. On the other hand, if you get a positive testing, you have to make a distinction for ctDNA in the minimal residual disease situation. If you get a positive test, there is enough evidence that the patient has a worse prognosis. There's evidence for that. No one can dispute that. Again, I'm talking about colorectal cancer where there are a lot of data for that. So, in that situation, there are studies that are looking, if you get a positive test in someone who you're not intending to give any adjuvant treatment, there are studies looking into that, both in terms of intensifying, like chemotherapy, in certain patients. And also, there's work being done, if you have a negative test in someone who has stage III disease, for example, or definitely stage II disease, they may not need to give them chemo. Those things are happening. But in metastatic disease, it's a different situation. Or even in someone who has received surgery, adjuvant chemotherapy, in those patients where they, whether they're now under, in the surveillance mode, those patients, if you have a positive, it may be positive. I had a recent patient like those, eight months before we saw anything on the scans. So, the question is, if you have a positive test, is there any advantage in giving them treatment, systemic treatment? Of course, we're assuming that the PET scan is negative. So, is there really any advantage in giving someone treatment ahead of time, before you see the imaging changes? That kind of data, in my opinion, is not really available or strong. You can always think of it in different ways, explain it in different ways. It's minimal disease, maybe you get a better response. But I don't know if we really can justify at this time. Therefore, in my practice, my own practice, I do not treat just a positive ctDNA. Again, that's different than after surgery when you're thinking of whether to give adjuvant treatment, no adjuvant treatment. But someone who's finished treatments and then you're just serially monitoring the disease, those patients, I do not treat them with chemotherapy. And that was something which, based on the literature we reviewed, there was nothing out there to definitely- I mean, if you see something positive, you will do a scan earlier, you will talk to the patient, examine the patient, whatever. But if there's nothing there, starting a treatment, that's not justified at this point in time. Now, you need to do a study like that. Definitely, you need to do a study. But I can tell you that from my experience, having been involved with study design and all that, it's not an easy trial to do. It's going to be a trial- at a minimum, it will take many patients, it will take longer time to complete, and there are a number of variables there. If someone is willing to put a lot of money into it, it can be done. But I can tell you that that kind of intention to do a study like that has been very much a challenge at this time. Dr. Rafeh Naqash: Of course, as you mentioned, the follow-up time that you need for a study like that is going to be very long to get to meaningful outcomes. Dr. Philip Philip: You need to be very patient to do such a study. But the problem with a very long study is that things change, standard of care changes with time, and the assays will change. So, that's why we don't have that kind of data. I'm not sure if there are people in the community or in the academic centers who do treat based on only positive ctDNA. The other thing is that you really have to always consider the psychological impact of these tests on patients and caregivers. Sometimes it can be really very stressful, burdensome to people to sit there just waiting for the disease to show up on a scan. And therefore, in my opinion, I'm not saying definitely don't use it in that situation, I'm just saying that you have to personalize it also, to see the patient who you would like to do it and then other patients who may not do it, or you think that it's not good for them to do it. And the patient also has to understand the outcome of the test and how you're going to be interpreting it. Dr. Rafeh Naqash: That's a lot of great insights, Dr. Philip, and I know you've been involved in trial designs. I'm sure NCT and cooperative groups are actively thinking and incorporating ctDNA-based metrics as one of the endpoints in their trial. I know of a GU study that's, I think it's an Alliance study, trying to de-escalate treatment based on ctDNA. I have one of my colleagues who's also a GU investigator at OU, he's doing a ctDNA-based, tumor-informed-based de-escalation. So, obviously, more and more data, hopefully, that'll be generated in the next couple of years. Dr. Philip Philip: But remember, these studies are not using it as an endpoint. They're using it as a means of optimizing treatment, which is a bit different. So, as an endpoint, can you do a phase III trial of, let's say, a thousand patients, and your primary endpoint is not survival, but you're saying, "Can I reduce the ctDNA, clear it earlier, or whatever?" That's the sort of thing this article was about. We can't do that at this time. Dr. Rafeh Naqash: I totally understand. Thank you for explaining the difference, and hopefully more to come in this space in the next couple of years. I briefly wanted to touch upon your personal career and journey based on all that you've done and accomplished. Could you tell us about how you started, what your journey has been like, and how that connects with what you're doing right now, including mentoring other trainees and junior faculty? Dr. Philip Philip: Well, when I was in high school, I wanted to be an engineer, but I grew up in Baghdad, and all my friends wanted to do medicine, so I went with the tide, so I did medicine. I don't regret that. I would do it again if I had the opportunity. The reason why I did oncology was, I left the country and did a PhD in clinical pharmacology at the University of London. And that really got me, it was a topic which included, which was on cancer. So, I really got interested in a disease that is really a lot of science, and things are new, or were new at the time. And if I want to look back what I was doing, the beginning of my training in the 80s, second half of the 80s, and now, it's unbelievable how things have changed. But one of the things which I really have to say is that almost all my life I've been in what we call academic institutions. But I firmly believe that for people, whether academic or not, you have to be a very good, astute clinician, because many of the things we do, really, we're trying to put the patients in the center. It's not only doing fancy science, it's to do things that help the patients. And you can bring in bits and pieces of fancy science or less fancy science, but that's something which is really extremely important for us to think about, being a very good clinician, very good doctor, because medicine is a science, whether you're practicing as a solo practitioner or you're part of a large academic center. It's the way you think, the way you interrogate things that you're not sure of, the way you collaborate, the way you learn every day. I mean, at my age, I still don't like to miss any tumor board, because in each tumor board, there's something you learn, even if you think that you know everything. So, that's really the whole thing of it, is that be a very good clinician, be open-minded. Always, you have to think of things that, they look interesting, they look somehow unexplained. Always try to help find the solutions and do that. One of the major things that I feel that people should do is being also very focused on things. I mean, you have to also know what you want to do in the next 5, 10, 15 years. Because although everyone is in it in the same way when we start, but there are different things that drive people, people who want to do more of the formal research, like being an academic-like institution. But there are also a lot of people who are very successful outside of a- what we call an academic setting. In the United States, most people are not working in an academic kind of setting. Although, for me, the distinction between academic and community is getting less and less, because if you think that you do phase I trials in academia only, that's not true, because there are, in fact, in the state of Michigan, the most active phase I doctor is not even in academia, he's in private practice. So, you can do all these things. It's a matter of what you like to do, and you really have to make sure you know what you want to do. Because sometimes people are, especially early on, they get a bit confused, “What I want to do.” There's an issue of doing general oncology versus subspecialist. If you're a subspecialist doing only GI, you have to make sure that you really also have some kind of recognition that you're only a GI oncologist, recognition regional, national, international, but some degree of recognition that you feel that people are coming to you for advice as a second opinion or whatever it is. But again, you have to decide what you think you want to be, how you want to be, because there's a lot of options here between community practice, academic practice, industry, and of course, there's always the administrative thing. Some people tend to be more like going into the line of being an administrator. So, there's a lot of options for you. Dr. Rafeh Naqash: Well, thank you again, Dr. Philip, for those pearls of wisdom. I think that was very insightful. I'm sure all the trainees and early-career investigators will find all that advice very helpful. Thank you again for joining us today. Thank you for listening to JCO Precision Oncology Conversations. Don't forget to give us a rating or review, and be sure to subscribe so you never miss an episode. You can find all ASCO shows at asco.org/podcast. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Dr. Philip Philip Disclosures Honoraria: Bayer, Ipsen, incyte, Taiho Pharmaceutical, Astellas Pharma, BioNTech SE, Novocure, TriSalus Life Sciences, SERVIER, Seagen Consulting or Advisory Role: Celgene, Ipsen, Merck, TriSalus Life Sciences, Daiichi Sankyo, SynCoreBio, Taiho Pharmaceutical Speakers' Bureau: Incyte Research Funding: Bayer (Inst), incyte (Inst), Merck (Inst), Taiho Pharmaceutical (Inst), novartis (Inst), Regeneron (Inst), Genentech (Inst), halozyme (Inst), Lilly (Inst), Taiho Pharmaceutical (Inst), merus (Inst), BioNTech SE (Inst) Uncompensated Relationships: Rafael Pharmaceuticals, Caris MPI  

This week we published an exclusive interview with Nicholas Kristof, an award-winning New York Times columnist. He spoke about what he saw in Sudan and the global community's failure to respond to one of the world's largest humanitarian crises — as the conflict in Gaza overshadows other crises around the world. As public attention wanes in the face of new crises, we question whether crisis fatigue is hindering humanitarian aid from reaching those in dire need. We also discussed a study that revealed European companies — including Siemens, BioNTech SE, Möller Group, and SUEZ — are benefiting from investments in over 60% of the EU Global Gateway projects examined. We dig into the study's details and whether Europe is doing enough to channel funds to the Global South and meet the needs of local communities. Meanwhile, in the United Kingdom, it appears as though the Department for International Development — which was merged with the Foreign and Commonwealth Office in 2020 — will not be restored anytime soon. We learned that British Prime Minister Keir Starmer rejected top-level advice that he could restore a separate U.K. aid department with “negligible” cost and disruption, according to a new book by former senior development officials. For the latest edition of our podcast series, Devex Managing Editor Anna Gawel sits down with reporters Elissa Miolene and Rob Merrick to discuss our top stories from the past week. Sign up to the Devex Newswire and our other newsletters: https://www.devex.com/account/newsletters

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC information, and to apply for credit, please visit us at PeerView.com/JSU865. CME/MOC credit will be available until March 22, 2025.The “Immunosurge” Continues: Moving in Leaps and Bounds to Expand the Role and Impact of Immunotherapy in Metastatic, Locally Advanced, and Early-Stage NSCLC In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerSandip Patel, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Amgen Inc; AstraZeneca; BeiGene, Inc.; Bristol Myers Squibb; Certis USA L.L.C.; Genentech, Inc.; Illumina, Inc.; Jazz Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Natera, Inc.; Pfizer Inc.; and Tempus.Grant/Research Support from Amgen Inc; AstraZeneca/MedImmune, Inc.; A2BIO; Bristol Myers Squibb; Fate Therapeutics; F. Hoffmann-La Roche Ltd/Genentech, Inc.; Gilead Sciences, Inc.; IOVANCE Biotherapeutics, Inc.; Lilly; Merck & Co., Inc.; and Pfizer Inc.Faculty/PlannerTina Cascone, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Bristol Myers Squibb; Genentech, Inc.; Merck & Co., Inc.; Pfizer Inc.; and Regeneron Pharmaceuticals Inc.Grant/Research Support from AstraZeneca and Bristol Myers Squibb.Faculty/PlannerJohn V. Heymach, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie Inc.; AnHeart Therapeutics; ArriVent Biopharma; AstraZeneca; BioCurity Pharmaceuticals; BioNTech SE; Blueprint Medicines Corporation; Boehringer Ingelheim International GmbH; Bristol Myers Squibb; Chugai Pharmaceutical Co., Ltd.; Curio Science; DAVA Oncology; EMD Serono, Inc.; F. Hoffmann-La Roche Ltd; Genentech, Inc.; GlaxoSmithKline; IDEOlogy Health; Immunocore Ltd; Janssen Biotech; Janssen Pharmaceuticals, Inc.; Lilly; Mirati Therapeutics, Inc.; Novartis Pharmaceuticals Corporation; Oncocyte Corporation; RefleXion; Regeneron Pharmaceuticals Inc.; Sandoz Group AG; sanofi-aventis U.S. LLC; Spectrum Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; uniQure NV; and Venn Biosciences.Grant/Research Support from AstraZeneca; Boehringer Ingelheim International GmbH; Spectrum Pharmaceuticals, Inc.; Mirati Therapeutics, Inc.; Bristol Myers Squibb; and Takeda Pharmaceutical Company Limited.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC information, and to apply for credit, please visit us at PeerView.com/JSU865. CME/MOC credit will be available until March 22, 2025.The “Immunosurge” Continues: Moving in Leaps and Bounds to Expand the Role and Impact of Immunotherapy in Metastatic, Locally Advanced, and Early-Stage NSCLC In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerSandip Patel, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Amgen Inc; AstraZeneca; BeiGene, Inc.; Bristol Myers Squibb; Certis USA L.L.C.; Genentech, Inc.; Illumina, Inc.; Jazz Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Natera, Inc.; Pfizer Inc.; and Tempus.Grant/Research Support from Amgen Inc; AstraZeneca/MedImmune, Inc.; A2BIO; Bristol Myers Squibb; Fate Therapeutics; F. Hoffmann-La Roche Ltd/Genentech, Inc.; Gilead Sciences, Inc.; IOVANCE Biotherapeutics, Inc.; Lilly; Merck & Co., Inc.; and Pfizer Inc.Faculty/PlannerTina Cascone, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Bristol Myers Squibb; Genentech, Inc.; Merck & Co., Inc.; Pfizer Inc.; and Regeneron Pharmaceuticals Inc.Grant/Research Support from AstraZeneca and Bristol Myers Squibb.Faculty/PlannerJohn V. Heymach, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie Inc.; AnHeart Therapeutics; ArriVent Biopharma; AstraZeneca; BioCurity Pharmaceuticals; BioNTech SE; Blueprint Medicines Corporation; Boehringer Ingelheim International GmbH; Bristol Myers Squibb; Chugai Pharmaceutical Co., Ltd.; Curio Science; DAVA Oncology; EMD Serono, Inc.; F. Hoffmann-La Roche Ltd; Genentech, Inc.; GlaxoSmithKline; IDEOlogy Health; Immunocore Ltd; Janssen Biotech; Janssen Pharmaceuticals, Inc.; Lilly; Mirati Therapeutics, Inc.; Novartis Pharmaceuticals Corporation; Oncocyte Corporation; RefleXion; Regeneron Pharmaceuticals Inc.; Sandoz Group AG; sanofi-aventis U.S. LLC; Spectrum Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; uniQure NV; and Venn Biosciences.Grant/Research Support from AstraZeneca; Boehringer Ingelheim International GmbH; Spectrum Pharmaceuticals, Inc.; Mirati Therapeutics, Inc.; Bristol Myers Squibb; and Takeda Pharmaceutical Company Limited.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC information, and to apply for credit, please visit us at PeerView.com/JSU865. CME/MOC credit will be available until March 22, 2025.The “Immunosurge” Continues: Moving in Leaps and Bounds to Expand the Role and Impact of Immunotherapy in Metastatic, Locally Advanced, and Early-Stage NSCLC In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerSandip Patel, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Amgen Inc; AstraZeneca; BeiGene, Inc.; Bristol Myers Squibb; Certis USA L.L.C.; Genentech, Inc.; Illumina, Inc.; Jazz Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Natera, Inc.; Pfizer Inc.; and Tempus.Grant/Research Support from Amgen Inc; AstraZeneca/MedImmune, Inc.; A2BIO; Bristol Myers Squibb; Fate Therapeutics; F. Hoffmann-La Roche Ltd/Genentech, Inc.; Gilead Sciences, Inc.; IOVANCE Biotherapeutics, Inc.; Lilly; Merck & Co., Inc.; and Pfizer Inc.Faculty/PlannerTina Cascone, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Bristol Myers Squibb; Genentech, Inc.; Merck & Co., Inc.; Pfizer Inc.; and Regeneron Pharmaceuticals Inc.Grant/Research Support from AstraZeneca and Bristol Myers Squibb.Faculty/PlannerJohn V. Heymach, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie Inc.; AnHeart Therapeutics; ArriVent Biopharma; AstraZeneca; BioCurity Pharmaceuticals; BioNTech SE; Blueprint Medicines Corporation; Boehringer Ingelheim International GmbH; Bristol Myers Squibb; Chugai Pharmaceutical Co., Ltd.; Curio Science; DAVA Oncology; EMD Serono, Inc.; F. Hoffmann-La Roche Ltd; Genentech, Inc.; GlaxoSmithKline; IDEOlogy Health; Immunocore Ltd; Janssen Biotech; Janssen Pharmaceuticals, Inc.; Lilly; Mirati Therapeutics, Inc.; Novartis Pharmaceuticals Corporation; Oncocyte Corporation; RefleXion; Regeneron Pharmaceuticals Inc.; Sandoz Group AG; sanofi-aventis U.S. LLC; Spectrum Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; uniQure NV; and Venn Biosciences.Grant/Research Support from AstraZeneca; Boehringer Ingelheim International GmbH; Spectrum Pharmaceuticals, Inc.; Mirati Therapeutics, Inc.; Bristol Myers Squibb; and Takeda Pharmaceutical Company Limited.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC information, and to apply for credit, please visit us at PeerView.com/JSU865. CME/MOC credit will be available until March 22, 2025.The “Immunosurge” Continues: Moving in Leaps and Bounds to Expand the Role and Impact of Immunotherapy in Metastatic, Locally Advanced, and Early-Stage NSCLC In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerSandip Patel, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Amgen Inc; AstraZeneca; BeiGene, Inc.; Bristol Myers Squibb; Certis USA L.L.C.; Genentech, Inc.; Illumina, Inc.; Jazz Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Natera, Inc.; Pfizer Inc.; and Tempus.Grant/Research Support from Amgen Inc; AstraZeneca/MedImmune, Inc.; A2BIO; Bristol Myers Squibb; Fate Therapeutics; F. Hoffmann-La Roche Ltd/Genentech, Inc.; Gilead Sciences, Inc.; IOVANCE Biotherapeutics, Inc.; Lilly; Merck & Co., Inc.; and Pfizer Inc.Faculty/PlannerTina Cascone, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Bristol Myers Squibb; Genentech, Inc.; Merck & Co., Inc.; Pfizer Inc.; and Regeneron Pharmaceuticals Inc.Grant/Research Support from AstraZeneca and Bristol Myers Squibb.Faculty/PlannerJohn V. Heymach, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie Inc.; AnHeart Therapeutics; ArriVent Biopharma; AstraZeneca; BioCurity Pharmaceuticals; BioNTech SE; Blueprint Medicines Corporation; Boehringer Ingelheim International GmbH; Bristol Myers Squibb; Chugai Pharmaceutical Co., Ltd.; Curio Science; DAVA Oncology; EMD Serono, Inc.; F. Hoffmann-La Roche Ltd; Genentech, Inc.; GlaxoSmithKline; IDEOlogy Health; Immunocore Ltd; Janssen Biotech; Janssen Pharmaceuticals, Inc.; Lilly; Mirati Therapeutics, Inc.; Novartis Pharmaceuticals Corporation; Oncocyte Corporation; RefleXion; Regeneron Pharmaceuticals Inc.; Sandoz Group AG; sanofi-aventis U.S. LLC; Spectrum Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; uniQure NV; and Venn Biosciences.Grant/Research Support from AstraZeneca; Boehringer Ingelheim International GmbH; Spectrum Pharmaceuticals, Inc.; Mirati Therapeutics, Inc.; Bristol Myers Squibb; and Takeda Pharmaceutical Company Limited.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC information, and to apply for credit, please visit us at PeerView.com/JSU865. CME/MOC credit will be available until March 22, 2025.The “Immunosurge” Continues: Moving in Leaps and Bounds to Expand the Role and Impact of Immunotherapy in Metastatic, Locally Advanced, and Early-Stage NSCLC In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerSandip Patel, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Amgen Inc; AstraZeneca; BeiGene, Inc.; Bristol Myers Squibb; Certis USA L.L.C.; Genentech, Inc.; Illumina, Inc.; Jazz Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Natera, Inc.; Pfizer Inc.; and Tempus.Grant/Research Support from Amgen Inc; AstraZeneca/MedImmune, Inc.; A2BIO; Bristol Myers Squibb; Fate Therapeutics; F. Hoffmann-La Roche Ltd/Genentech, Inc.; Gilead Sciences, Inc.; IOVANCE Biotherapeutics, Inc.; Lilly; Merck & Co., Inc.; and Pfizer Inc.Faculty/PlannerTina Cascone, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Bristol Myers Squibb; Genentech, Inc.; Merck & Co., Inc.; Pfizer Inc.; and Regeneron Pharmaceuticals Inc.Grant/Research Support from AstraZeneca and Bristol Myers Squibb.Faculty/PlannerJohn V. Heymach, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie Inc.; AnHeart Therapeutics; ArriVent Biopharma; AstraZeneca; BioCurity Pharmaceuticals; BioNTech SE; Blueprint Medicines Corporation; Boehringer Ingelheim International GmbH; Bristol Myers Squibb; Chugai Pharmaceutical Co., Ltd.; Curio Science; DAVA Oncology; EMD Serono, Inc.; F. Hoffmann-La Roche Ltd; Genentech, Inc.; GlaxoSmithKline; IDEOlogy Health; Immunocore Ltd; Janssen Biotech; Janssen Pharmaceuticals, Inc.; Lilly; Mirati Therapeutics, Inc.; Novartis Pharmaceuticals Corporation; Oncocyte Corporation; RefleXion; Regeneron Pharmaceuticals Inc.; Sandoz Group AG; sanofi-aventis U.S. LLC; Spectrum Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; uniQure NV; and Venn Biosciences.Grant/Research Support from AstraZeneca; Boehringer Ingelheim International GmbH; Spectrum Pharmaceuticals, Inc.; Mirati Therapeutics, Inc.; Bristol Myers Squibb; and Takeda Pharmaceutical Company Limited.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC information, and to apply for credit, please visit us at PeerView.com/JSU865. CME/MOC credit will be available until March 22, 2025.The “Immunosurge” Continues: Moving in Leaps and Bounds to Expand the Role and Impact of Immunotherapy in Metastatic, Locally Advanced, and Early-Stage NSCLC In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerSandip Patel, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Amgen Inc; AstraZeneca; BeiGene, Inc.; Bristol Myers Squibb; Certis USA L.L.C.; Genentech, Inc.; Illumina, Inc.; Jazz Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Natera, Inc.; Pfizer Inc.; and Tempus.Grant/Research Support from Amgen Inc; AstraZeneca/MedImmune, Inc.; A2BIO; Bristol Myers Squibb; Fate Therapeutics; F. Hoffmann-La Roche Ltd/Genentech, Inc.; Gilead Sciences, Inc.; IOVANCE Biotherapeutics, Inc.; Lilly; Merck & Co., Inc.; and Pfizer Inc.Faculty/PlannerTina Cascone, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Bristol Myers Squibb; Genentech, Inc.; Merck & Co., Inc.; Pfizer Inc.; and Regeneron Pharmaceuticals Inc.Grant/Research Support from AstraZeneca and Bristol Myers Squibb.Faculty/PlannerJohn V. Heymach, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie Inc.; AnHeart Therapeutics; ArriVent Biopharma; AstraZeneca; BioCurity Pharmaceuticals; BioNTech SE; Blueprint Medicines Corporation; Boehringer Ingelheim International GmbH; Bristol Myers Squibb; Chugai Pharmaceutical Co., Ltd.; Curio Science; DAVA Oncology; EMD Serono, Inc.; F. Hoffmann-La Roche Ltd; Genentech, Inc.; GlaxoSmithKline; IDEOlogy Health; Immunocore Ltd; Janssen Biotech; Janssen Pharmaceuticals, Inc.; Lilly; Mirati Therapeutics, Inc.; Novartis Pharmaceuticals Corporation; Oncocyte Corporation; RefleXion; Regeneron Pharmaceuticals Inc.; Sandoz Group AG; sanofi-aventis U.S. LLC; Spectrum Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; uniQure NV; and Venn Biosciences.Grant/Research Support from AstraZeneca; Boehringer Ingelheim International GmbH; Spectrum Pharmaceuticals, Inc.; Mirati Therapeutics, Inc.; Bristol Myers Squibb; and Takeda Pharmaceutical Company Limited.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC information, and to apply for credit, please visit us at PeerView.com/JSU865. CME/MOC credit will be available until March 22, 2025.The “Immunosurge” Continues: Moving in Leaps and Bounds to Expand the Role and Impact of Immunotherapy in Metastatic, Locally Advanced, and Early-Stage NSCLC In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerSandip Patel, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Amgen Inc; AstraZeneca; BeiGene, Inc.; Bristol Myers Squibb; Certis USA L.L.C.; Genentech, Inc.; Illumina, Inc.; Jazz Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Natera, Inc.; Pfizer Inc.; and Tempus.Grant/Research Support from Amgen Inc; AstraZeneca/MedImmune, Inc.; A2BIO; Bristol Myers Squibb; Fate Therapeutics; F. Hoffmann-La Roche Ltd/Genentech, Inc.; Gilead Sciences, Inc.; IOVANCE Biotherapeutics, Inc.; Lilly; Merck & Co., Inc.; and Pfizer Inc.Faculty/PlannerTina Cascone, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Bristol Myers Squibb; Genentech, Inc.; Merck & Co., Inc.; Pfizer Inc.; and Regeneron Pharmaceuticals Inc.Grant/Research Support from AstraZeneca and Bristol Myers Squibb.Faculty/PlannerJohn V. Heymach, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie Inc.; AnHeart Therapeutics; ArriVent Biopharma; AstraZeneca; BioCurity Pharmaceuticals; BioNTech SE; Blueprint Medicines Corporation; Boehringer Ingelheim International GmbH; Bristol Myers Squibb; Chugai Pharmaceutical Co., Ltd.; Curio Science; DAVA Oncology; EMD Serono, Inc.; F. Hoffmann-La Roche Ltd; Genentech, Inc.; GlaxoSmithKline; IDEOlogy Health; Immunocore Ltd; Janssen Biotech; Janssen Pharmaceuticals, Inc.; Lilly; Mirati Therapeutics, Inc.; Novartis Pharmaceuticals Corporation; Oncocyte Corporation; RefleXion; Regeneron Pharmaceuticals Inc.; Sandoz Group AG; sanofi-aventis U.S. LLC; Spectrum Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; uniQure NV; and Venn Biosciences.Grant/Research Support from AstraZeneca; Boehringer Ingelheim International GmbH; Spectrum Pharmaceuticals, Inc.; Mirati Therapeutics, Inc.; Bristol Myers Squibb; and Takeda Pharmaceutical Company Limited.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC information, and to apply for credit, please visit us at PeerView.com/JSU865. CME/MOC credit will be available until March 22, 2025.The “Immunosurge” Continues: Moving in Leaps and Bounds to Expand the Role and Impact of Immunotherapy in Metastatic, Locally Advanced, and Early-Stage NSCLC In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerSandip Patel, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Amgen Inc; AstraZeneca; BeiGene, Inc.; Bristol Myers Squibb; Certis USA L.L.C.; Genentech, Inc.; Illumina, Inc.; Jazz Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Natera, Inc.; Pfizer Inc.; and Tempus.Grant/Research Support from Amgen Inc; AstraZeneca/MedImmune, Inc.; A2BIO; Bristol Myers Squibb; Fate Therapeutics; F. Hoffmann-La Roche Ltd/Genentech, Inc.; Gilead Sciences, Inc.; IOVANCE Biotherapeutics, Inc.; Lilly; Merck & Co., Inc.; and Pfizer Inc.Faculty/PlannerTina Cascone, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Bristol Myers Squibb; Genentech, Inc.; Merck & Co., Inc.; Pfizer Inc.; and Regeneron Pharmaceuticals Inc.Grant/Research Support from AstraZeneca and Bristol Myers Squibb.Faculty/PlannerJohn V. Heymach, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie Inc.; AnHeart Therapeutics; ArriVent Biopharma; AstraZeneca; BioCurity Pharmaceuticals; BioNTech SE; Blueprint Medicines Corporation; Boehringer Ingelheim International GmbH; Bristol Myers Squibb; Chugai Pharmaceutical Co., Ltd.; Curio Science; DAVA Oncology; EMD Serono, Inc.; F. Hoffmann-La Roche Ltd; Genentech, Inc.; GlaxoSmithKline; IDEOlogy Health; Immunocore Ltd; Janssen Biotech; Janssen Pharmaceuticals, Inc.; Lilly; Mirati Therapeutics, Inc.; Novartis Pharmaceuticals Corporation; Oncocyte Corporation; RefleXion; Regeneron Pharmaceuticals Inc.; Sandoz Group AG; sanofi-aventis U.S. LLC; Spectrum Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; uniQure NV; and Venn Biosciences.Grant/Research Support from AstraZeneca; Boehringer Ingelheim International GmbH; Spectrum Pharmaceuticals, Inc.; Mirati Therapeutics, Inc.; Bristol Myers Squibb; and Takeda Pharmaceutical Company Limited.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CC/AAPA information, and to apply for credit, please visit us at PeerView.com/QRX865. CME/MOC/CC/AAPA credit will be available until February 27, 2025.A Practical Guide for Making Multidisciplinary Decisions About Neoadjuvant and/or Adjuvant Immunotherapy in Resectable NSCLC In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca, Bristol Myers Squibb, and Merck & Co., Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerJessica Donington, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Amgen; AstraZeneca; Bristol Myers Squibb; Genentech, Inc./F. Hoffmann-La Roche Ltd.; and Merck & Co., Inc.Grant/Research Support from AstraZeneca; Bristol Myers Squibb; Genentech, Inc./F. Hoffmann-La Roche Ltd.; and Merck & Co., Inc.Co-Chair/PlannerJonathan D. Spicer, MD, PhD, FRCSC, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Bristol Myers Squibb; Chemocentryx; F. Hoffmann-La Roche Ltd.; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Protalix Biotherapeutics; Regeneron; and Xenetic Biosciences.Grant/Research Support from AstraZeneca; Bristol Myers Squibb; CLS Therapeutics; F. Hoffmann-La Roche Ltd.; Merck & Co., Inc.; and Protalix Biotherapeutics.Faculty/PlannerPatrick M. Forde, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Amgen Inc.; Ascendis Pharma A/S; AstraZeneca; Bristol Myers Squibb; CureVac SE; F-star Therapeutics Inc.; Flame Pharmaceuticals Pvt Ltd; Fosun Pharma USA Inc.; G1 Therapeutics, Inc.; Genelux Corporation; Genentech, Inc.; Gritstone bio, Inc.; iTeos Therapeutics; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Regeneron Pharmaceuticals Inc.; Sanofi; Synthekine; Tavotek Biotherapeutics; and Teva Pharmaceuticals USA, Inc.Grant/Research Support from AstraZeneca; BioNTech SE; Bristol Myers Squibb; Novartis Pharmaceuticals Corporation; and Regeneron Pharmaceuticals Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CC/AAPA information, and to apply for credit, please visit us at PeerView.com/QRX865. CME/MOC/CC/AAPA credit will be available until February 27, 2025.A Practical Guide for Making Multidisciplinary Decisions About Neoadjuvant and/or Adjuvant Immunotherapy in Resectable NSCLC In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca, Bristol Myers Squibb, and Merck & Co., Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerJessica Donington, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Amgen; AstraZeneca; Bristol Myers Squibb; Genentech, Inc./F. Hoffmann-La Roche Ltd.; and Merck & Co., Inc.Grant/Research Support from AstraZeneca; Bristol Myers Squibb; Genentech, Inc./F. Hoffmann-La Roche Ltd.; and Merck & Co., Inc.Co-Chair/PlannerJonathan D. Spicer, MD, PhD, FRCSC, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Bristol Myers Squibb; Chemocentryx; F. Hoffmann-La Roche Ltd.; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Protalix Biotherapeutics; Regeneron; and Xenetic Biosciences.Grant/Research Support from AstraZeneca; Bristol Myers Squibb; CLS Therapeutics; F. Hoffmann-La Roche Ltd.; Merck & Co., Inc.; and Protalix Biotherapeutics.Faculty/PlannerPatrick M. Forde, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Amgen Inc.; Ascendis Pharma A/S; AstraZeneca; Bristol Myers Squibb; CureVac SE; F-star Therapeutics Inc.; Flame Pharmaceuticals Pvt Ltd; Fosun Pharma USA Inc.; G1 Therapeutics, Inc.; Genelux Corporation; Genentech, Inc.; Gritstone bio, Inc.; iTeos Therapeutics; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Regeneron Pharmaceuticals Inc.; Sanofi; Synthekine; Tavotek Biotherapeutics; and Teva Pharmaceuticals USA, Inc.Grant/Research Support from AstraZeneca; BioNTech SE; Bristol Myers Squibb; Novartis Pharmaceuticals Corporation; and Regeneron Pharmaceuticals Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CC/AAPA information, and to apply for credit, please visit us at PeerView.com/QRX865. CME/MOC/CC/AAPA credit will be available until February 27, 2025.A Practical Guide for Making Multidisciplinary Decisions About Neoadjuvant and/or Adjuvant Immunotherapy in Resectable NSCLC In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca, Bristol Myers Squibb, and Merck & Co., Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerJessica Donington, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Amgen; AstraZeneca; Bristol Myers Squibb; Genentech, Inc./F. Hoffmann-La Roche Ltd.; and Merck & Co., Inc.Grant/Research Support from AstraZeneca; Bristol Myers Squibb; Genentech, Inc./F. Hoffmann-La Roche Ltd.; and Merck & Co., Inc.Co-Chair/PlannerJonathan D. Spicer, MD, PhD, FRCSC, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Bristol Myers Squibb; Chemocentryx; F. Hoffmann-La Roche Ltd.; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Protalix Biotherapeutics; Regeneron; and Xenetic Biosciences.Grant/Research Support from AstraZeneca; Bristol Myers Squibb; CLS Therapeutics; F. Hoffmann-La Roche Ltd.; Merck & Co., Inc.; and Protalix Biotherapeutics.Faculty/PlannerPatrick M. Forde, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Amgen Inc.; Ascendis Pharma A/S; AstraZeneca; Bristol Myers Squibb; CureVac SE; F-star Therapeutics Inc.; Flame Pharmaceuticals Pvt Ltd; Fosun Pharma USA Inc.; G1 Therapeutics, Inc.; Genelux Corporation; Genentech, Inc.; Gritstone bio, Inc.; iTeos Therapeutics; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Regeneron Pharmaceuticals Inc.; Sanofi; Synthekine; Tavotek Biotherapeutics; and Teva Pharmaceuticals USA, Inc.Grant/Research Support from AstraZeneca; BioNTech SE; Bristol Myers Squibb; Novartis Pharmaceuticals Corporation; and Regeneron Pharmaceuticals Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CC/AAPA information, and to apply for credit, please visit us at PeerView.com/QRX865. CME/MOC/CC/AAPA credit will be available until February 27, 2025.A Practical Guide for Making Multidisciplinary Decisions About Neoadjuvant and/or Adjuvant Immunotherapy in Resectable NSCLC In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca, Bristol Myers Squibb, and Merck & Co., Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerJessica Donington, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Amgen; AstraZeneca; Bristol Myers Squibb; Genentech, Inc./F. Hoffmann-La Roche Ltd.; and Merck & Co., Inc.Grant/Research Support from AstraZeneca; Bristol Myers Squibb; Genentech, Inc./F. Hoffmann-La Roche Ltd.; and Merck & Co., Inc.Co-Chair/PlannerJonathan D. Spicer, MD, PhD, FRCSC, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Bristol Myers Squibb; Chemocentryx; F. Hoffmann-La Roche Ltd.; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Protalix Biotherapeutics; Regeneron; and Xenetic Biosciences.Grant/Research Support from AstraZeneca; Bristol Myers Squibb; CLS Therapeutics; F. Hoffmann-La Roche Ltd.; Merck & Co., Inc.; and Protalix Biotherapeutics.Faculty/PlannerPatrick M. Forde, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Amgen Inc.; Ascendis Pharma A/S; AstraZeneca; Bristol Myers Squibb; CureVac SE; F-star Therapeutics Inc.; Flame Pharmaceuticals Pvt Ltd; Fosun Pharma USA Inc.; G1 Therapeutics, Inc.; Genelux Corporation; Genentech, Inc.; Gritstone bio, Inc.; iTeos Therapeutics; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Regeneron Pharmaceuticals Inc.; Sanofi; Synthekine; Tavotek Biotherapeutics; and Teva Pharmaceuticals USA, Inc.Grant/Research Support from AstraZeneca; BioNTech SE; Bristol Myers Squibb; Novartis Pharmaceuticals Corporation; and Regeneron Pharmaceuticals Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CC/AAPA information, and to apply for credit, please visit us at PeerView.com/QRX865. CME/MOC/CC/AAPA credit will be available until February 27, 2025.A Practical Guide for Making Multidisciplinary Decisions About Neoadjuvant and/or Adjuvant Immunotherapy in Resectable NSCLC In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca, Bristol Myers Squibb, and Merck & Co., Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerJessica Donington, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Amgen; AstraZeneca; Bristol Myers Squibb; Genentech, Inc./F. Hoffmann-La Roche Ltd.; and Merck & Co., Inc.Grant/Research Support from AstraZeneca; Bristol Myers Squibb; Genentech, Inc./F. Hoffmann-La Roche Ltd.; and Merck & Co., Inc.Co-Chair/PlannerJonathan D. Spicer, MD, PhD, FRCSC, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Bristol Myers Squibb; Chemocentryx; F. Hoffmann-La Roche Ltd.; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Protalix Biotherapeutics; Regeneron; and Xenetic Biosciences.Grant/Research Support from AstraZeneca; Bristol Myers Squibb; CLS Therapeutics; F. Hoffmann-La Roche Ltd.; Merck & Co., Inc.; and Protalix Biotherapeutics.Faculty/PlannerPatrick M. Forde, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Amgen Inc.; Ascendis Pharma A/S; AstraZeneca; Bristol Myers Squibb; CureVac SE; F-star Therapeutics Inc.; Flame Pharmaceuticals Pvt Ltd; Fosun Pharma USA Inc.; G1 Therapeutics, Inc.; Genelux Corporation; Genentech, Inc.; Gritstone bio, Inc.; iTeos Therapeutics; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Regeneron Pharmaceuticals Inc.; Sanofi; Synthekine; Tavotek Biotherapeutics; and Teva Pharmaceuticals USA, Inc.Grant/Research Support from AstraZeneca; BioNTech SE; Bristol Myers Squibb; Novartis Pharmaceuticals Corporation; and Regeneron Pharmaceuticals Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CC/AAPA information, and to apply for credit, please visit us at PeerView.com/QRX865. CME/MOC/CC/AAPA credit will be available until February 27, 2025.A Practical Guide for Making Multidisciplinary Decisions About Neoadjuvant and/or Adjuvant Immunotherapy in Resectable NSCLC In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca, Bristol Myers Squibb, and Merck & Co., Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerJessica Donington, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Amgen; AstraZeneca; Bristol Myers Squibb; Genentech, Inc./F. Hoffmann-La Roche Ltd.; and Merck & Co., Inc.Grant/Research Support from AstraZeneca; Bristol Myers Squibb; Genentech, Inc./F. Hoffmann-La Roche Ltd.; and Merck & Co., Inc.Co-Chair/PlannerJonathan D. Spicer, MD, PhD, FRCSC, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Bristol Myers Squibb; Chemocentryx; F. Hoffmann-La Roche Ltd.; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Protalix Biotherapeutics; Regeneron; and Xenetic Biosciences.Grant/Research Support from AstraZeneca; Bristol Myers Squibb; CLS Therapeutics; F. Hoffmann-La Roche Ltd.; Merck & Co., Inc.; and Protalix Biotherapeutics.Faculty/PlannerPatrick M. Forde, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Amgen Inc.; Ascendis Pharma A/S; AstraZeneca; Bristol Myers Squibb; CureVac SE; F-star Therapeutics Inc.; Flame Pharmaceuticals Pvt Ltd; Fosun Pharma USA Inc.; G1 Therapeutics, Inc.; Genelux Corporation; Genentech, Inc.; Gritstone bio, Inc.; iTeos Therapeutics; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Regeneron Pharmaceuticals Inc.; Sanofi; Synthekine; Tavotek Biotherapeutics; and Teva Pharmaceuticals USA, Inc.Grant/Research Support from AstraZeneca; BioNTech SE; Bristol Myers Squibb; Novartis Pharmaceuticals Corporation; and Regeneron Pharmaceuticals Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CC/AAPA information, and to apply for credit, please visit us at PeerView.com/QRX865. CME/MOC/CC/AAPA credit will be available until February 27, 2025.A Practical Guide for Making Multidisciplinary Decisions About Neoadjuvant and/or Adjuvant Immunotherapy in Resectable NSCLC In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca, Bristol Myers Squibb, and Merck & Co., Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerJessica Donington, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Amgen; AstraZeneca; Bristol Myers Squibb; Genentech, Inc./F. Hoffmann-La Roche Ltd.; and Merck & Co., Inc.Grant/Research Support from AstraZeneca; Bristol Myers Squibb; Genentech, Inc./F. Hoffmann-La Roche Ltd.; and Merck & Co., Inc.Co-Chair/PlannerJonathan D. Spicer, MD, PhD, FRCSC, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Bristol Myers Squibb; Chemocentryx; F. Hoffmann-La Roche Ltd.; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Protalix Biotherapeutics; Regeneron; and Xenetic Biosciences.Grant/Research Support from AstraZeneca; Bristol Myers Squibb; CLS Therapeutics; F. Hoffmann-La Roche Ltd.; Merck & Co., Inc.; and Protalix Biotherapeutics.Faculty/PlannerPatrick M. Forde, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Amgen Inc.; Ascendis Pharma A/S; AstraZeneca; Bristol Myers Squibb; CureVac SE; F-star Therapeutics Inc.; Flame Pharmaceuticals Pvt Ltd; Fosun Pharma USA Inc.; G1 Therapeutics, Inc.; Genelux Corporation; Genentech, Inc.; Gritstone bio, Inc.; iTeos Therapeutics; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Regeneron Pharmaceuticals Inc.; Sanofi; Synthekine; Tavotek Biotherapeutics; and Teva Pharmaceuticals USA, Inc.Grant/Research Support from AstraZeneca; BioNTech SE; Bristol Myers Squibb; Novartis Pharmaceuticals Corporation; and Regeneron Pharmaceuticals Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CC/AAPA information, and to apply for credit, please visit us at PeerView.com/QRX865. CME/MOC/CC/AAPA credit will be available until February 27, 2025.A Practical Guide for Making Multidisciplinary Decisions About Neoadjuvant and/or Adjuvant Immunotherapy in Resectable NSCLC In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca, Bristol Myers Squibb, and Merck & Co., Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerJessica Donington, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Amgen; AstraZeneca; Bristol Myers Squibb; Genentech, Inc./F. Hoffmann-La Roche Ltd.; and Merck & Co., Inc.Grant/Research Support from AstraZeneca; Bristol Myers Squibb; Genentech, Inc./F. Hoffmann-La Roche Ltd.; and Merck & Co., Inc.Co-Chair/PlannerJonathan D. Spicer, MD, PhD, FRCSC, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Bristol Myers Squibb; Chemocentryx; F. Hoffmann-La Roche Ltd.; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Protalix Biotherapeutics; Regeneron; and Xenetic Biosciences.Grant/Research Support from AstraZeneca; Bristol Myers Squibb; CLS Therapeutics; F. Hoffmann-La Roche Ltd.; Merck & Co., Inc.; and Protalix Biotherapeutics.Faculty/PlannerPatrick M. Forde, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Amgen Inc.; Ascendis Pharma A/S; AstraZeneca; Bristol Myers Squibb; CureVac SE; F-star Therapeutics Inc.; Flame Pharmaceuticals Pvt Ltd; Fosun Pharma USA Inc.; G1 Therapeutics, Inc.; Genelux Corporation; Genentech, Inc.; Gritstone bio, Inc.; iTeos Therapeutics; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Regeneron Pharmaceuticals Inc.; Sanofi; Synthekine; Tavotek Biotherapeutics; and Teva Pharmaceuticals USA, Inc.Grant/Research Support from AstraZeneca; BioNTech SE; Bristol Myers Squibb; Novartis Pharmaceuticals Corporation; and Regeneron Pharmaceuticals Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/ZZA865. CME/MOC/AAPA credit will be available until January 2, 2025.Harnessing the Power of the Latest Clinical and Research Advances in SCLC: How to Accelerate Progress and Improve Patient Outcomes With Current and Emerging Therapies In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerTaofeek K. Owonikoko, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Abbvie Inc.; Amgen Inc.; AstraZeneca; Bayer Corporation; BeiGene, Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Coherus BioSciences; Daiichi Sankyo, Inc.; Eisai Inc.; EMD Serono, Inc.; Exelixis, Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; G1 Therapeutics, Inc.; GenCART; Heat Biologics Inc.; Ipsen Pharma; Janssen Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Meryx Inc.; Novartis Pharmaceuticals Corporation; Oncocyte Corporation; PharmaMar; Takeda Pharmaceutical Company Limited; Xcovery; and Zentalis Pharmaceuticals.Grant/Research Support from Aeglea BioTherapeutics; Amgen Inc.; AstraZeneca; Bayer Corporation; Bristol Myers Squibb; Cardiff Oncology, Inc.; Eisai Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; FUJIFILM Pharmaceuticals U.S.A., Inc.; G1 Therapeutics, Inc.; Incyte; Ipsen Pharma; Loxo Oncology/Lilly; Merck & Co., Inc.; Mersana Therapeutics; Novartis Pharmaceuticals Corporation; Oncorus, Inc.; Pfizer; Regeneron Pharmaceuticals Inc.; Turning Point Therapeutics, Inc.; United Therapeutics Corporation; and Y-mAbs Therapeutics, Inc.Faculty/PlannerHossein Borghaei, DO, MS, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Amgen Inc.; AstraZeneca; Axiom; Bayer Corporation; BeiGene, Inc.; BerGenbio; BioNTech SE; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Da Volterra; Daiichi Sankyo, Inc.; EMD Serono, Inc.; Genentech, Inc.; Genmab A/S; Grid Therapeutics; Guardant Health; IO Biotech, Inc.; iTeos Therapeutics; Janssen Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Mirati Therapeutics, Inc.; Natera; Novartis Pharmaceuticals Corporation; Oncocyte Corporation; Pfizer; PharmaMar; Puma Biotechnology; Regeneron Pharmaceuticals Inc.; and Takeda Pharmaceutical Company Limited.Grant/Research Support from Amgen Inc.; Bristol Myers Squibb; and Lilly.Data Safety Monitoring Board for Incyte; Novartis Pharmaceuticals Corporation; SpringWorks Therapeutics, Inc.; Takeda Pharmaceutical Company Limited; and University of Pennsylvania: CAR T Program.Faculty/PlannerAnne Chiang, MD, PhD, FASCO, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Daiichi Sankyo, Inc.; Genentech, Inc.; and Janssen Pharmaceuticals, Inc.Grant/Research Support from AbbVie Inc.; Amgen Inc.; AstraZeneca; Bristol Myers Squibb; Flatiron Health; and Genentech, Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/ZZA865. CME/MOC/AAPA credit will be available until January 2, 2025.Harnessing the Power of the Latest Clinical and Research Advances in SCLC: How to Accelerate Progress and Improve Patient Outcomes With Current and Emerging Therapies In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerTaofeek K. Owonikoko, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Abbvie Inc.; Amgen Inc.; AstraZeneca; Bayer Corporation; BeiGene, Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Coherus BioSciences; Daiichi Sankyo, Inc.; Eisai Inc.; EMD Serono, Inc.; Exelixis, Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; G1 Therapeutics, Inc.; GenCART; Heat Biologics Inc.; Ipsen Pharma; Janssen Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Meryx Inc.; Novartis Pharmaceuticals Corporation; Oncocyte Corporation; PharmaMar; Takeda Pharmaceutical Company Limited; Xcovery; and Zentalis Pharmaceuticals.Grant/Research Support from Aeglea BioTherapeutics; Amgen Inc.; AstraZeneca; Bayer Corporation; Bristol Myers Squibb; Cardiff Oncology, Inc.; Eisai Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; FUJIFILM Pharmaceuticals U.S.A., Inc.; G1 Therapeutics, Inc.; Incyte; Ipsen Pharma; Loxo Oncology/Lilly; Merck & Co., Inc.; Mersana Therapeutics; Novartis Pharmaceuticals Corporation; Oncorus, Inc.; Pfizer; Regeneron Pharmaceuticals Inc.; Turning Point Therapeutics, Inc.; United Therapeutics Corporation; and Y-mAbs Therapeutics, Inc.Faculty/PlannerHossein Borghaei, DO, MS, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Amgen Inc.; AstraZeneca; Axiom; Bayer Corporation; BeiGene, Inc.; BerGenbio; BioNTech SE; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Da Volterra; Daiichi Sankyo, Inc.; EMD Serono, Inc.; Genentech, Inc.; Genmab A/S; Grid Therapeutics; Guardant Health; IO Biotech, Inc.; iTeos Therapeutics; Janssen Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Mirati Therapeutics, Inc.; Natera; Novartis Pharmaceuticals Corporation; Oncocyte Corporation; Pfizer; PharmaMar; Puma Biotechnology; Regeneron Pharmaceuticals Inc.; and Takeda Pharmaceutical Company Limited.Grant/Research Support from Amgen Inc.; Bristol Myers Squibb; and Lilly.Data Safety Monitoring Board for Incyte; Novartis Pharmaceuticals Corporation; SpringWorks Therapeutics, Inc.; Takeda Pharmaceutical Company Limited; and University of Pennsylvania: CAR T Program.Faculty/PlannerAnne Chiang, MD, PhD, FASCO, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Daiichi Sankyo, Inc.; Genentech, Inc.; and Janssen Pharmaceuticals, Inc.Grant/Research Support from AbbVie Inc.; Amgen Inc.; AstraZeneca; Bristol Myers Squibb; Flatiron Health; and Genentech, Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/ZZA865. CME/MOC/AAPA credit will be available until January 2, 2025.Harnessing the Power of the Latest Clinical and Research Advances in SCLC: How to Accelerate Progress and Improve Patient Outcomes With Current and Emerging Therapies In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerTaofeek K. Owonikoko, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Abbvie Inc.; Amgen Inc.; AstraZeneca; Bayer Corporation; BeiGene, Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Coherus BioSciences; Daiichi Sankyo, Inc.; Eisai Inc.; EMD Serono, Inc.; Exelixis, Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; G1 Therapeutics, Inc.; GenCART; Heat Biologics Inc.; Ipsen Pharma; Janssen Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Meryx Inc.; Novartis Pharmaceuticals Corporation; Oncocyte Corporation; PharmaMar; Takeda Pharmaceutical Company Limited; Xcovery; and Zentalis Pharmaceuticals.Grant/Research Support from Aeglea BioTherapeutics; Amgen Inc.; AstraZeneca; Bayer Corporation; Bristol Myers Squibb; Cardiff Oncology, Inc.; Eisai Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; FUJIFILM Pharmaceuticals U.S.A., Inc.; G1 Therapeutics, Inc.; Incyte; Ipsen Pharma; Loxo Oncology/Lilly; Merck & Co., Inc.; Mersana Therapeutics; Novartis Pharmaceuticals Corporation; Oncorus, Inc.; Pfizer; Regeneron Pharmaceuticals Inc.; Turning Point Therapeutics, Inc.; United Therapeutics Corporation; and Y-mAbs Therapeutics, Inc.Faculty/PlannerHossein Borghaei, DO, MS, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Amgen Inc.; AstraZeneca; Axiom; Bayer Corporation; BeiGene, Inc.; BerGenbio; BioNTech SE; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Da Volterra; Daiichi Sankyo, Inc.; EMD Serono, Inc.; Genentech, Inc.; Genmab A/S; Grid Therapeutics; Guardant Health; IO Biotech, Inc.; iTeos Therapeutics; Janssen Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Mirati Therapeutics, Inc.; Natera; Novartis Pharmaceuticals Corporation; Oncocyte Corporation; Pfizer; PharmaMar; Puma Biotechnology; Regeneron Pharmaceuticals Inc.; and Takeda Pharmaceutical Company Limited.Grant/Research Support from Amgen Inc.; Bristol Myers Squibb; and Lilly.Data Safety Monitoring Board for Incyte; Novartis Pharmaceuticals Corporation; SpringWorks Therapeutics, Inc.; Takeda Pharmaceutical Company Limited; and University of Pennsylvania: CAR T Program.Faculty/PlannerAnne Chiang, MD, PhD, FASCO, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Daiichi Sankyo, Inc.; Genentech, Inc.; and Janssen Pharmaceuticals, Inc.Grant/Research Support from AbbVie Inc.; Amgen Inc.; AstraZeneca; Bristol Myers Squibb; Flatiron Health; and Genentech, Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/ZZA865. CME/MOC/AAPA credit will be available until January 2, 2025.Harnessing the Power of the Latest Clinical and Research Advances in SCLC: How to Accelerate Progress and Improve Patient Outcomes With Current and Emerging Therapies In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerTaofeek K. Owonikoko, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Abbvie Inc.; Amgen Inc.; AstraZeneca; Bayer Corporation; BeiGene, Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Coherus BioSciences; Daiichi Sankyo, Inc.; Eisai Inc.; EMD Serono, Inc.; Exelixis, Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; G1 Therapeutics, Inc.; GenCART; Heat Biologics Inc.; Ipsen Pharma; Janssen Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Meryx Inc.; Novartis Pharmaceuticals Corporation; Oncocyte Corporation; PharmaMar; Takeda Pharmaceutical Company Limited; Xcovery; and Zentalis Pharmaceuticals.Grant/Research Support from Aeglea BioTherapeutics; Amgen Inc.; AstraZeneca; Bayer Corporation; Bristol Myers Squibb; Cardiff Oncology, Inc.; Eisai Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; FUJIFILM Pharmaceuticals U.S.A., Inc.; G1 Therapeutics, Inc.; Incyte; Ipsen Pharma; Loxo Oncology/Lilly; Merck & Co., Inc.; Mersana Therapeutics; Novartis Pharmaceuticals Corporation; Oncorus, Inc.; Pfizer; Regeneron Pharmaceuticals Inc.; Turning Point Therapeutics, Inc.; United Therapeutics Corporation; and Y-mAbs Therapeutics, Inc.Faculty/PlannerHossein Borghaei, DO, MS, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Amgen Inc.; AstraZeneca; Axiom; Bayer Corporation; BeiGene, Inc.; BerGenbio; BioNTech SE; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Da Volterra; Daiichi Sankyo, Inc.; EMD Serono, Inc.; Genentech, Inc.; Genmab A/S; Grid Therapeutics; Guardant Health; IO Biotech, Inc.; iTeos Therapeutics; Janssen Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Mirati Therapeutics, Inc.; Natera; Novartis Pharmaceuticals Corporation; Oncocyte Corporation; Pfizer; PharmaMar; Puma Biotechnology; Regeneron Pharmaceuticals Inc.; and Takeda Pharmaceutical Company Limited.Grant/Research Support from Amgen Inc.; Bristol Myers Squibb; and Lilly.Data Safety Monitoring Board for Incyte; Novartis Pharmaceuticals Corporation; SpringWorks Therapeutics, Inc.; Takeda Pharmaceutical Company Limited; and University of Pennsylvania: CAR T Program.Faculty/PlannerAnne Chiang, MD, PhD, FASCO, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Daiichi Sankyo, Inc.; Genentech, Inc.; and Janssen Pharmaceuticals, Inc.Grant/Research Support from AbbVie Inc.; Amgen Inc.; AstraZeneca; Bristol Myers Squibb; Flatiron Health; and Genentech, Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/ZZA865. CME/MOC/AAPA credit will be available until January 2, 2025.Harnessing the Power of the Latest Clinical and Research Advances in SCLC: How to Accelerate Progress and Improve Patient Outcomes With Current and Emerging Therapies In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerTaofeek K. Owonikoko, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Abbvie Inc.; Amgen Inc.; AstraZeneca; Bayer Corporation; BeiGene, Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Coherus BioSciences; Daiichi Sankyo, Inc.; Eisai Inc.; EMD Serono, Inc.; Exelixis, Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; G1 Therapeutics, Inc.; GenCART; Heat Biologics Inc.; Ipsen Pharma; Janssen Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Meryx Inc.; Novartis Pharmaceuticals Corporation; Oncocyte Corporation; PharmaMar; Takeda Pharmaceutical Company Limited; Xcovery; and Zentalis Pharmaceuticals.Grant/Research Support from Aeglea BioTherapeutics; Amgen Inc.; AstraZeneca; Bayer Corporation; Bristol Myers Squibb; Cardiff Oncology, Inc.; Eisai Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; FUJIFILM Pharmaceuticals U.S.A., Inc.; G1 Therapeutics, Inc.; Incyte; Ipsen Pharma; Loxo Oncology/Lilly; Merck & Co., Inc.; Mersana Therapeutics; Novartis Pharmaceuticals Corporation; Oncorus, Inc.; Pfizer; Regeneron Pharmaceuticals Inc.; Turning Point Therapeutics, Inc.; United Therapeutics Corporation; and Y-mAbs Therapeutics, Inc.Faculty/PlannerHossein Borghaei, DO, MS, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Amgen Inc.; AstraZeneca; Axiom; Bayer Corporation; BeiGene, Inc.; BerGenbio; BioNTech SE; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Da Volterra; Daiichi Sankyo, Inc.; EMD Serono, Inc.; Genentech, Inc.; Genmab A/S; Grid Therapeutics; Guardant Health; IO Biotech, Inc.; iTeos Therapeutics; Janssen Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Mirati Therapeutics, Inc.; Natera; Novartis Pharmaceuticals Corporation; Oncocyte Corporation; Pfizer; PharmaMar; Puma Biotechnology; Regeneron Pharmaceuticals Inc.; and Takeda Pharmaceutical Company Limited.Grant/Research Support from Amgen Inc.; Bristol Myers Squibb; and Lilly.Data Safety Monitoring Board for Incyte; Novartis Pharmaceuticals Corporation; SpringWorks Therapeutics, Inc.; Takeda Pharmaceutical Company Limited; and University of Pennsylvania: CAR T Program.Faculty/PlannerAnne Chiang, MD, PhD, FASCO, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Daiichi Sankyo, Inc.; Genentech, Inc.; and Janssen Pharmaceuticals, Inc.Grant/Research Support from AbbVie Inc.; Amgen Inc.; AstraZeneca; Bristol Myers Squibb; Flatiron Health; and Genentech, Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/ZZA865. CME/MOC/AAPA credit will be available until January 2, 2025.Harnessing the Power of the Latest Clinical and Research Advances in SCLC: How to Accelerate Progress and Improve Patient Outcomes With Current and Emerging Therapies In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerTaofeek K. Owonikoko, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Abbvie Inc.; Amgen Inc.; AstraZeneca; Bayer Corporation; BeiGene, Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Coherus BioSciences; Daiichi Sankyo, Inc.; Eisai Inc.; EMD Serono, Inc.; Exelixis, Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; G1 Therapeutics, Inc.; GenCART; Heat Biologics Inc.; Ipsen Pharma; Janssen Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Meryx Inc.; Novartis Pharmaceuticals Corporation; Oncocyte Corporation; PharmaMar; Takeda Pharmaceutical Company Limited; Xcovery; and Zentalis Pharmaceuticals.Grant/Research Support from Aeglea BioTherapeutics; Amgen Inc.; AstraZeneca; Bayer Corporation; Bristol Myers Squibb; Cardiff Oncology, Inc.; Eisai Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; FUJIFILM Pharmaceuticals U.S.A., Inc.; G1 Therapeutics, Inc.; Incyte; Ipsen Pharma; Loxo Oncology/Lilly; Merck & Co., Inc.; Mersana Therapeutics; Novartis Pharmaceuticals Corporation; Oncorus, Inc.; Pfizer; Regeneron Pharmaceuticals Inc.; Turning Point Therapeutics, Inc.; United Therapeutics Corporation; and Y-mAbs Therapeutics, Inc.Faculty/PlannerHossein Borghaei, DO, MS, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Amgen Inc.; AstraZeneca; Axiom; Bayer Corporation; BeiGene, Inc.; BerGenbio; BioNTech SE; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Da Volterra; Daiichi Sankyo, Inc.; EMD Serono, Inc.; Genentech, Inc.; Genmab A/S; Grid Therapeutics; Guardant Health; IO Biotech, Inc.; iTeos Therapeutics; Janssen Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Mirati Therapeutics, Inc.; Natera; Novartis Pharmaceuticals Corporation; Oncocyte Corporation; Pfizer; PharmaMar; Puma Biotechnology; Regeneron Pharmaceuticals Inc.; and Takeda Pharmaceutical Company Limited.Grant/Research Support from Amgen Inc.; Bristol Myers Squibb; and Lilly.Data Safety Monitoring Board for Incyte; Novartis Pharmaceuticals Corporation; SpringWorks Therapeutics, Inc.; Takeda Pharmaceutical Company Limited; and University of Pennsylvania: CAR T Program.Faculty/PlannerAnne Chiang, MD, PhD, FASCO, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Daiichi Sankyo, Inc.; Genentech, Inc.; and Janssen Pharmaceuticals, Inc.Grant/Research Support from AbbVie Inc.; Amgen Inc.; AstraZeneca; Bristol Myers Squibb; Flatiron Health; and Genentech, Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/ZZA865. CME/MOC/AAPA credit will be available until January 2, 2025.Harnessing the Power of the Latest Clinical and Research Advances in SCLC: How to Accelerate Progress and Improve Patient Outcomes With Current and Emerging Therapies In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerTaofeek K. Owonikoko, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Abbvie Inc.; Amgen Inc.; AstraZeneca; Bayer Corporation; BeiGene, Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Coherus BioSciences; Daiichi Sankyo, Inc.; Eisai Inc.; EMD Serono, Inc.; Exelixis, Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; G1 Therapeutics, Inc.; GenCART; Heat Biologics Inc.; Ipsen Pharma; Janssen Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Meryx Inc.; Novartis Pharmaceuticals Corporation; Oncocyte Corporation; PharmaMar; Takeda Pharmaceutical Company Limited; Xcovery; and Zentalis Pharmaceuticals.Grant/Research Support from Aeglea BioTherapeutics; Amgen Inc.; AstraZeneca; Bayer Corporation; Bristol Myers Squibb; Cardiff Oncology, Inc.; Eisai Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; FUJIFILM Pharmaceuticals U.S.A., Inc.; G1 Therapeutics, Inc.; Incyte; Ipsen Pharma; Loxo Oncology/Lilly; Merck & Co., Inc.; Mersana Therapeutics; Novartis Pharmaceuticals Corporation; Oncorus, Inc.; Pfizer; Regeneron Pharmaceuticals Inc.; Turning Point Therapeutics, Inc.; United Therapeutics Corporation; and Y-mAbs Therapeutics, Inc.Faculty/PlannerHossein Borghaei, DO, MS, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Amgen Inc.; AstraZeneca; Axiom; Bayer Corporation; BeiGene, Inc.; BerGenbio; BioNTech SE; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Da Volterra; Daiichi Sankyo, Inc.; EMD Serono, Inc.; Genentech, Inc.; Genmab A/S; Grid Therapeutics; Guardant Health; IO Biotech, Inc.; iTeos Therapeutics; Janssen Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Mirati Therapeutics, Inc.; Natera; Novartis Pharmaceuticals Corporation; Oncocyte Corporation; Pfizer; PharmaMar; Puma Biotechnology; Regeneron Pharmaceuticals Inc.; and Takeda Pharmaceutical Company Limited.Grant/Research Support from Amgen Inc.; Bristol Myers Squibb; and Lilly.Data Safety Monitoring Board for Incyte; Novartis Pharmaceuticals Corporation; SpringWorks Therapeutics, Inc.; Takeda Pharmaceutical Company Limited; and University of Pennsylvania: CAR T Program.Faculty/PlannerAnne Chiang, MD, PhD, FASCO, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Daiichi Sankyo, Inc.; Genentech, Inc.; and Janssen Pharmaceuticals, Inc.Grant/Research Support from AbbVie Inc.; Amgen Inc.; AstraZeneca; Bristol Myers Squibb; Flatiron Health; and Genentech, Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/ZZA865. CME/MOC/AAPA credit will be available until January 2, 2025.Harnessing the Power of the Latest Clinical and Research Advances in SCLC: How to Accelerate Progress and Improve Patient Outcomes With Current and Emerging Therapies In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerTaofeek K. Owonikoko, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Abbvie Inc.; Amgen Inc.; AstraZeneca; Bayer Corporation; BeiGene, Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Coherus BioSciences; Daiichi Sankyo, Inc.; Eisai Inc.; EMD Serono, Inc.; Exelixis, Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; G1 Therapeutics, Inc.; GenCART; Heat Biologics Inc.; Ipsen Pharma; Janssen Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Meryx Inc.; Novartis Pharmaceuticals Corporation; Oncocyte Corporation; PharmaMar; Takeda Pharmaceutical Company Limited; Xcovery; and Zentalis Pharmaceuticals.Grant/Research Support from Aeglea BioTherapeutics; Amgen Inc.; AstraZeneca; Bayer Corporation; Bristol Myers Squibb; Cardiff Oncology, Inc.; Eisai Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; FUJIFILM Pharmaceuticals U.S.A., Inc.; G1 Therapeutics, Inc.; Incyte; Ipsen Pharma; Loxo Oncology/Lilly; Merck & Co., Inc.; Mersana Therapeutics; Novartis Pharmaceuticals Corporation; Oncorus, Inc.; Pfizer; Regeneron Pharmaceuticals Inc.; Turning Point Therapeutics, Inc.; United Therapeutics Corporation; and Y-mAbs Therapeutics, Inc.Faculty/PlannerHossein Borghaei, DO, MS, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Amgen Inc.; AstraZeneca; Axiom; Bayer Corporation; BeiGene, Inc.; BerGenbio; BioNTech SE; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Da Volterra; Daiichi Sankyo, Inc.; EMD Serono, Inc.; Genentech, Inc.; Genmab A/S; Grid Therapeutics; Guardant Health; IO Biotech, Inc.; iTeos Therapeutics; Janssen Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Mirati Therapeutics, Inc.; Natera; Novartis Pharmaceuticals Corporation; Oncocyte Corporation; Pfizer; PharmaMar; Puma Biotechnology; Regeneron Pharmaceuticals Inc.; and Takeda Pharmaceutical Company Limited.Grant/Research Support from Amgen Inc.; Bristol Myers Squibb; and Lilly.Data Safety Monitoring Board for Incyte; Novartis Pharmaceuticals Corporation; SpringWorks Therapeutics, Inc.; Takeda Pharmaceutical Company Limited; and University of Pennsylvania: CAR T Program.Faculty/PlannerAnne Chiang, MD, PhD, FASCO, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Daiichi Sankyo, Inc.; Genentech, Inc.; and Janssen Pharmaceuticals, Inc.Grant/Research Support from AbbVie Inc.; Amgen Inc.; AstraZeneca; Bristol Myers Squibb; Flatiron Health; and Genentech, Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

In der neuesten Folge des AWS Cloud Horizonte Podcasts besuchen Tim Schröder und Daniel Gburek von BioNTech SE, Heinrich Nikonow von AWS in München. Das Interview dreht sich um die Nutzung von AI und ML in der Biotechnologie, die Herausforderungen bei der Implementierung und die Realisierung von AI-Anwendungsfällen und Use Cases, insbesondere mithilfe der Data Analytics Plattform BioNData. BioNTech hat schon früh den Mehrwert von AI in der Arzneimittelforschung erkannt, vor allen Dingen gegen Krebs und Infektionskrankheiten. In Bezug auf die Produktion strebt BioNTech nach effizienteren und schnelleren Lösungen, zum Beispiel durch die Automatisierung von Systemen an seinen Produktionsstandorten. Diese Podcastfolge bietet spannende Einblicke in die Verwendung von AI und ML in der Biotechnologie und zeigt auf, wie BioNTech diese Technologien einsetzt, um innovative Lösungen voranzutreiben. Hört unbedingt rein und erfahrt mehr über die faszinierenden Entwicklungen im Bereich der Biotechnologie und den Einsatz von AI und ML!

US equity markets closed out a tough week on a positive note as investors parsed the latest monthly jobs report - Dow gained +402-points or +1.26%, The broader S&P500 climbed +1.36%, PayPal Holdings Inc fell -1.79% after the company trimmed their revenue full year guidance results after the closing bell of last Thursday's (3 November) session, with Chief Executive Dan Schulman noting that PayPal was “seeing a pullback in discretionary goods that are being spent on by consumers.” The Nasdaq rose +1.28%. Meta Platforms Inc (up +2.11%) is planning to begin large-scale layoffs this week according to a report in The Wall Street Journal. The small capitalisation Russell 2000 +1.13%. BioNTech SE rose +6.24% after China approved the biotechnology company's mRNA COVID-19 vaccine for use among the expatriate population in the People's Republic of China. During German Chancellor Olaf Scholz's visit to Beijing, he and Chinese leader, Xi Jinping, also broached the subject of a pathway for approval of the vaccine for use among the wider Chinese population, The Wall Street Journal reported. Separately, BioNTech and partner Pfizer Inc (up +1.40%) said new data from a Phase 2/3 trial showed that the booster for companies' omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine demonstrated a "robust neutralizing immune response" after one month. The companies said immune responses for those getting the booster were "substantially higher" than for those who only received the original COVID-19 vaccine, with similar safety and tolerability profiles. Carvana Co tumbled -38.95% to post its worst single session performance on record after the on-line used car retailer reported disappointing third-quarter results after the closing bell of last Thursday's (3 November) session that prompted Morgan Stanley to pull their rating and price target on the company, citing deterioration in the used car market and a volatile funding environment. Friday also saw the expiration of weekly and daily options tied to single stocks, stock indexes and exchange-traded funds (ETFs).

US equity markets closed out a tough week on a positive note as investors parsed the latest monthly jobs report - Dow gained +402-points or +1.26%, The broader S&P500 climbed +1.36%, PayPal Holdings Inc fell -1.79% after the company trimmed their revenue full year guidance results after the closing bell of last Thursday's (3 November) session, with Chief Executive Dan Schulman noting that PayPal was “seeing a pullback in discretionary goods that are being spent on by consumers.” The Nasdaq rose +1.28%. Meta Platforms Inc (up +2.11%) is planning to begin large-scale layoffs this week according to a report in The Wall Street Journal. The small capitalisation Russell 2000 +1.13%. BioNTech SE rose +6.24% after China approved the biotechnology company's mRNA COVID-19 vaccine for use among the expatriate population in the People's Republic of China. During German Chancellor Olaf Scholz's visit to Beijing, he and Chinese leader, Xi Jinping, also broached the subject of a pathway for approval of the vaccine for use among the wider Chinese population, The Wall Street Journal reported. Separately, BioNTech and partner Pfizer Inc (up +1.40%) said new data from a Phase 2/3 trial showed that the booster for companies' omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine demonstrated a "robust neutralizing immune response" after one month. The companies said immune responses for those getting the booster were "substantially higher" than for those who only received the original COVID-19 vaccine, with similar safety and tolerability profiles. Carvana Co tumbled -38.95% to post its worst single session performance on record after the on-line used car retailer reported disappointing third-quarter results after the closing bell of last Thursday's (3 November) session that prompted Morgan Stanley to pull their rating and price target on the company, citing deterioration in the used car market and a volatile funding environment. Friday also saw the expiration of weekly and daily options tied to single stocks, stock indexes and exchange-traded funds (ETFs).

Professor Katalin Karikó's research led to the creation of the messenger RNA Covid-19 vaccine, which has saved so many lives and helped curb the impact of the pandemic. She has quite literally changed the world! Ilham sits down with Professor Karikó to talk about her invaluable research; her passion for science; her upbringing in Hungary; women in science, technology, engineering and math (STEM) careers; her advice for young scientists, and much more1:42 - Upbringing in Hungary5:26 - Move to the United States7:43 - Development of the Covid-19 vaccine11:23 - mRNA technology as a potential solution for other diseases13:49 - Receiving the covid-19 vaccine - the results of her work15:19 - Story of resilience and determination amid challenges21:15 - Adjusting to almost overnight fame22:50 - Educating the public24:06 - Championing women scientists24:44 - Role models28:28 - Advice to young scientistsProfessor Katalin Karikó is an adjunct professor at the University of Pennsylvania, where she worked for 24 years before joining BioNTech SE in 2013 as a senior VP. She is also professor at University of Szeged, Hungary from where she received her PhD in biochemistry in 1982. For decades, her research has focused on RNA-mediated mechanisms with the ultimate goal of developing mRNA for protein therapy. She investigated RNA-mediated immune activation and together with Drew Weissman discovered that nucleoside modifications suppress the immunogenicity of RNA, which widened the therapeutic potentials of mRNA. Her patent, co-invented with Drew Weissman, was used to create the FDA-approved covid-19 mRNA vaccines by BioNTech/Pfizer and Moderna. Her groundbreaking contribution was to use chemistry to modify the mRNA so that it wouldn't be rejected by the immune system. In the future, her research could be applied to many other diseases such as cancer, influenza, malaria, tuberculosis, and so much more. Professor Karikó has won numerous awards for her incredible work, including the Solvay Prize.  For additional details about the podcast, show notes, and access to resources mentioned during the show, please visit https://www.solvay.com/podcast

US equity markets logged modest gains ahead of the Federal Reserve kicking off their latest two day monetary policy meeting tonight AEST - Dow up +197-points or +0.64%, recovering from an earlier session decline of as much as -263-points. The broader S&P500 added +0.69%, with Materials (up +1.63%), Consumer Discretionary (+1.34%), Industrials (+1.33%), Utilities (+1.32%) and Financials (+1.12%) all rebounded over >1% to lead nine of the eleven primary sectors higher. Healthcare (down -0.54%) and Real Estate (-0.21%) were the only primary sectors to close in the red. Vaccine manufacturers Pfizer Inc (-1.28%), Moderna Inc (down -7.14%), BioNTech SE (-8.60%) and Novavax Inc (-6.51%) all declined a day after President Joe Biden said in a CBS interview that "the pandemic is over". Ford Motor Co fell over >4% in extended trading after the automaker told investors it saw a +US$1B increase in supply chain costs during the third quarter. Ford reiterated its full-year guidance for adjusted earnings before interest and taxes (EBIT) of between US$11.5B and US$12.5B. The company is slated to release its third quarter result on 26 October. The Nasdaq rose +0.76%. Chipmaker Nvidia Corp (up +1.39%) hosts a GTC Financial Analyst Q&A tonight AEST. The small capitalisation Russell 2000 gained +0.81%.

US equity markets logged modest gains ahead of the Federal Reserve kicking off their latest two day monetary policy meeting tonight AEST - Dow up +197-points or +0.64%, recovering from an earlier session decline of as much as -263-points. The broader S&P500 added +0.69%, with Materials (up +1.63%), Consumer Discretionary (+1.34%), Industrials (+1.33%), Utilities (+1.32%) and Financials (+1.12%) all rebounded over >1% to lead nine of the eleven primary sectors higher. Healthcare (down -0.54%) and Real Estate (-0.21%) were the only primary sectors to close in the red. Vaccine manufacturers Pfizer Inc (-1.28%), Moderna Inc (down -7.14%), BioNTech SE (-8.60%) and Novavax Inc (-6.51%) all declined a day after President Joe Biden said in a CBS interview that "the pandemic is over". Ford Motor Co fell over >4% in extended trading after the automaker told investors it saw a +US$1B increase in supply chain costs during the third quarter. Ford reiterated its full-year guidance for adjusted earnings before interest and taxes (EBIT) of between US$11.5B and US$12.5B. The company is slated to release its third quarter result on 26 October. The Nasdaq rose +0.76%. Chipmaker Nvidia Corp (up +1.39%) hosts a GTC Financial Analyst Q&A tonight AEST. The small capitalisation Russell 2000 gained +0.81%.

Ghana, Rwanda and Senegal have partnered with German biotechnology company, BioNTech SE, to fill, finish, and package BioNTech mRNA vaccines in Africa. Germany, President Nana Addo Dankwa Akufo-Addo and President Macky Sall of Senegal, as well as President Paul Kagame of Rwanda, witnessed the official presentation of a BioNTech modular production facility, for the production of mRNA vaccines in Africa. The BioNTainer is equipped to manufacture a range of mRNA-based approved vaccines specifically to the needs of African member states.

Laboratorios portátiles de BioNTech / Se incendia un barco lleno de coches eléctricos / Google prueba un diseño polémico / Windows 11 Pro te obligará a tener cuenta con Microsoft / Perseverance cumple un año en Marte Patrocinador: Si estás buscando directivos, o perfiles altamente cualificados para tu empresa, y no sabes por dónde empezar, Randstad Professionals https://www.randstad.es/imparables/, la consultora de selección del grupo Randstad, te ayuda a seleccionarlos, con su equipo especializado por sectores y puestos. — Descubre más en randstad.es/imparables https://www.randstad.es/imparables/. Laboratorios portátiles de BioNTech / Se incendia un barco lleno de coches eléctricos / Google prueba un diseño polémico / Windows 11 Pro te obligará a tener cuenta con Microsoft / Perseverance cumple un año en Marte

Holyoke Media, en asociación con WHMP radio, emiten diariamente la Síntesis informativa en español a través del 101.5 FM y en el 1240 / 1400 AM. Esta es la síntesis informativa del jueves 6 de enero de 2022: - Un panel de expertos externos que asesoraron al Centro para el Control y la Prevención de Enfermedades (CDC) votó el miércoles para recomendar que las vacunas de refuerzo de Pfizer y la vacuna COVID-19 de BioNTech SE estén disponibles para menores de 12 a 15 años de edad. El panel también dijo que el CDC debería fortalecer su recomendación para los refuerzos de 16 y 17 años. La agencia ya había puesto las vacunas a disposición de esos adolescentes, pero no llegó a sugerir que todos deberían recibir el refuerzo adicional. Los casos de COVID-19 en los Estados Unidos han alcanzado niveles récord en los últimos días debido a la rápida propagación de la variante ómicron del virus. Las tasas de infección están aumentando a medida que muchos trabajadores y niños en edad escolar regresan de las vacaciones, lo que aumenta la posibilidad de sistemas de salud abrumados, así como de negocios y escuelas cerradas. FUENTE: REUTERS - El presidente Joe Biden les dirá a los estadounidenses que su predecesor, Donald Trump, tiene una "responsabilidad singular" por el ataque mortal del 6 de enero contra el Capitolio, cuando se conmemora el primer aniversario del ataque este jueves, dijo la Casa Blanca. Biden y la vicepresidenta Kamala Harris, ambos demócratas, hablarán este jueves por la mañana en el Capitolio de los Estados Unidos, un año después de que una turba leal a Trump allanara el complejo en un intento fallido de detener la certificación de los votos del Colegio Electoral que oficialmente entregó la victoria electoral de Biden. Biden y sus principales asesores se han mostrado reacios a hablar directamente sobre Trump desde que el exsenador asumió el cargo en enero pasado, incluso cuando el expresidente republicano continuaba difundiendo mentiras sobre su derrota electoral, y los demócratas, historiadores y activistas de derechos civiles se han preocupado cada vez más por el futuro de la democracia representativa de casi 250 años. El discurso del jueves se produce después de que Biden pasó meses alentando a los estadounidenses a unirse contra la pandemia de COVID-19 y reconstruir juntos después de los desastres climáticos. El jueves, Biden “expondrá el significado de lo que sucedió en el Capitolio y la responsabilidad singular que tiene el presidente Trump por el caos y la carnicería que vimos y rechazará por la fuerza las mentiras difundidas por el expresidente en un intento de engañar al pueblo estadounidense y sus propios seguidores, además de distraer la atención de su papel en lo que sucedió ", dijo la secretaria de prensa de la Casa Blanca, Jen Psaki. Por otra parte, Trump canceló una conferencia de prensa en su finca de Mar-a-Lago en Florida que había sido programada para el jueves por la noche, culpando a lo que llamó "parcialidad y deshonestidad" de la investigación de la Cámara de Representantes de los ataques y a los medios de comunicación, uno de sus objetivos favoritos. FUENTE: REUTERS

Welcome to The Nonlinear Library, where we use Text-to-Speech software to convert the best writing from the Rationalist and EA communities into audio. This is: The 300-year journey to the covid vaccine, published by jasoncrawford on the LessWrong. This is a linkpost for A covid vaccine has demonstrated 90% efficacy and no significant safety concerns in preliminary data from Phase 3 trials, according to an announcement today from Pfizer and BioNTech SE. The trials aren't yet complete and the data hasn't yet been released for independent verification, but this is very good news. (More from STAT News.) Pfizer/BioNTech's vaccine, like Moderna's, is based on “mRNA” technology. If approved by the FDA, it will be the first such vaccine to reach that milestone. From a long-term progress perspective, this is a big deal. Immunization technology has existed since the early 1700s (and the folk practices it originated in go back centuries further.) We can see the whole 300-year history of the technology as a quest to achieve immunity with ever-more safety and ever-fewer side effects. More recently, it has also become important to be able to react quickly to new epidemics, such as covid. Here's how immunization has advanced in stages: Inoculation All immunization is based on the observation that exposure to a disease often grants immunity (temporary if not permanent) to subsequent exposure. Long before we knew anything about antibodies or T-cells, people had noticed this simple correlation. Many people got smallpox in the past, but almost no one got it twice. The goal of immunization technology is to achieve that same immunity, but without having to suffer the disease or to risk death or other side effects. The earliest form of immunization, then, was not a vaccine, but a method in which the patient was given the actual disease itself, in a manner that would cause a mild rather than a severe case of the illness. This was done with smallpox, and the technique was called inoculation or variolation. This worked with smallpox for two reasons. One, infectious material was easy to obtain, from the pustules caused by the disease itself. Second, contracting the disease through a scratch on the skin caused a much more mild form than contracting it more naturally through inhalation. Inoculation saved many people from smallpox. But there were downsides. First, the patient still had to contract the disease, causing mild symptoms. Second, there was still a small risk of a severe case; even the best inoculation methods had about a 0.2% death rate. Third, the patient was still contagious while going through the illness, and anyone who caught the disease naturally from an inoculated patient would get the full, severe version. Inoculation thus risked outbreaks. Vaccination These problems were solved by the next stage: vaccination. It was observed that cowpox infection granted some form of cross-immunity to smallpox. Thus, the inoculation procedure could be performed using cowpox material, rather than smallpox. Cowpox was a milder and non-lethal disease. This reduced the symptoms and the risk of death, and eliminated the risk of smallpox outbreaks as a result of immunization. This new technique, invented by Edward Jenner in 1796, was called vaccination (from vacca, the Latin word for cow). So far, however, the technique only worked for smallpox—not for tuberculosis, malaria, influenza, cholera, or any of the other major diseases that caused something like half of all deaths in that era. Engineered vaccines The next stage would wait almost ninety years. Louis Pasteur, a pioneer of microbiology who along with Robert Koch established the germ theory, was the first to discover how to create vaccines for any disease other than smallpox. Cowpox can be seen as a “natural vaccine” against smallpox: a natural virus that grants smallpox immunity but produces milder side effects. Pasteur's accomplishment was to create artificial, engineered vaccines. There are essen...

AMONG the headlines for Friday, October 8, 2021, the Ministry of Health earlier today announced it's conditional approval for the Comirnaty vaccine to be used as a booster shot, at least six months after the second dose for those aged 18 and above. Health Director-General Tan Sri Dr Noor Hisham Abdullah said this is the first Covid-19 vaccine approved as a booster dose in the country. He said the decision was made during the 365th Drug Control Authority meeting today. Also,  Pfizer and BioNTech SE submitted initial trial data for their COVID-19 vaccine in 5-11 year olds. The drugmakers said they would make a formal request to U.S. regulators for emergency use in the coming weeks. Listen to the top stories of the day, reporting from Astro AWANI newsroom — all in 3-minutes. We bring you the headlines, weekdays at 5 pm. Stay informed on astroawani.com for these news and more.

The Delta variant of the Covid-19 virus, the dominant strain in the U.S., is driving up cases in particular where vaccination rates are lower. Also known as B.1.617.2, the variant was first identified in India in late 2020. It has spread to at least 85 countries, according to the World Health Organization, and has itself mutated to produce a further version that is causing concern in India. Vaccines from Moderna Inc., Johnson & Johnson and Pfizer Inc. and partner BioNTech SE—the three shots authorized in the U.S.—were primarily tested in large clinical trials for their efficacy at preventing symptomatic disease, rather than their ability to prevent infection completely. While the vaccines seem to be slightly less effective at preventing symptomatic Covid-19 from the Delta variant, research has shown that they remain highly effective at preventing serious illness and hospitalization. Overall, the portion of eligible Americans fully vaccinated against Covid-19 has been stalled for weeks at around 57%. Here is what we know so far about the Delta variant and vaccines. --- This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app Support this podcast: https://anchor.fm/yaar-ben-emmett/support

郭台銘台積電各買500萬劑BNT疫苗 傳已達初步協議 https://www.cna.com.tw/news/firstnews/202107030007.aspx 3名知情人士告訴路透社，鴻海集團創辦人郭台銘和台積電今天已達成初步協議，各自購買德國生技公司BioNTech SE 500萬劑新冠疫苗。 台灣政府已嘗試數個月直接向BNT購買疫苗，但指責中國阻礙雙方本於今年初達成的協議。中方否認這項指控。 路透獨家報導，3名消息人士表示，郭台銘和台積電今天與BNT代理商上海復星醫藥達成初步協議並簽署法律文件，各採購BNT疫苗500萬劑。上海復星醫藥與BNT簽有合約，在中國、香港、澳門和台灣銷售COVID-19疫苗。 1名消息人士說，這並非最終合約，仍需一段時間才能完成交易。他說協議簽訂仍需「相關法律文件」才能完成，至於疫苗交貨日期則未具體說明，因全球疫苗仍供應吃緊。 這名消息人士表示，疫苗將由這家德國疫苗製造商直接運送來台。 鴻海集團或上海復興醫藥在非營運時間內，均未回應置評要求。 台積電在簡短電郵聲明中指出，目前仍在洽談爭取疫苗，「目前無法提供進一步資訊」。 BNT也不願發表評論。另1名消息人士則說，德國政府一直表示願意幫助台灣取得BNT疫苗，加快談判速度。 這名消息人士說：「德國政府不願留下一個印象，即他們是在中國施壓下才不出售疫苗給台灣，所以德國政府一直推促這家公司加快與台灣方面的談判。」消息人士指的是BNT。 對於這項說法，德國外交部不願立即置評。 鏡周刊：【BNT買到了】買成了！　鴻海、台積電最快8月進口BNT疫苗 https://www.mirrormedia.mg/story/20210703inv001/ 路透社引述3名消息人士指出，鴻海集團創辦人郭台銘和台積電週五（7/2）與德國生技公司BioNTech代理商復星醫藥達成初步協議，3方已共同簽署採購文件，將各自進口500萬劑BNT疫苗（即輝瑞疫苗）來台，鴻海及台積電2家公司尚未正式回應，但相關人士向本刊透露，2家公司將下週上班日正式發布重訊，公布採購金額及內容，採購的現貨疫苗不會少於一千萬劑，將分批來台，最快第一批貨8月就會從德國原廠進口。 EXCLUSIVE Taiwan's Terry Gou, TSMC reach initial agreements for BioNTech vaccines -sources https://www.reuters.com/business/healthcare-pharmaceuticals/exclusive-taiwans-terry-gou-tsmc-reach-initial-agreements-biontech-vaccines-2021-07-02/ 台積電、鴻海買BNT有進展？ 陳時中：都還順利 https://www.cna.com.tw/news/ahel/202107030111.aspx 給長輩的AZ疫苗懶人包 https://linshibi.com/?p=39590 高端 聯亞 國產疫苗懶人包 第二期結束就緊急授權可行嗎？ https://linshibi.com/?p=39547 新冠快篩懶人包 普篩 抗體快篩 抗原快篩 https://linshibi.com/?p=36564 新冠肺炎疫情下的防疫須知 常見問題解答FAQ https://linshibi.com/?p=35408 新冠疫苗常見問題懶人包 https://linshibi.com/?p=38945 林氏璧醫師的電子名片 https://lit.link/linshibi 歡迎贊助我喝咖啡 https://pay.firstory.me/user/linshibi Powered by Firstory Hosting

Taiwanese Buddhist group hopes to buy 5 million doses of BioNTech SE's vaccine. Group joins Foxconn and TSMC in trying to secure vaccines for the island. Taiwan's government has millions of vaccines on order but has been hampered by global supply shortages.

The Union Health Ministry requested all the states and Union Territories to prioritise the beneficiaries of the second dose of the COVID-19 vaccine. Pfizer & BioNTech SE today announced the initiation of a Biologics License Application with US Food & Drug Administration for approval of their mRNA vaccine to prevent COVID19 in individuals of 16 years of age and older. For more live news download Etv Bharat Download ETV Bharat on App store – https://apps.apple.com/in/app/etv-bharat/id1453416186 Play Store – https://play.google.com/store/apps/details?id=com.etvbharat.android Or watch us live on – www.etvbharat.com ETV Bharat is d Division of Ushodaya Enterprises Pvt. Ltd. , is a comprehensive digital national news platform conceived to deliver seamless news and information services, using video-centric Mobile App and Web Portals. It is first-of-its kind offering in India in terms of diversity and depth, dedicated journalists network, reach of 24 states with services in 13 languages i.e.– Hindi, Urdu, Telugu, Tamil, Kannada, Malayalam, Gujarati, Marathi, Bengali, Punjabi, Assamese, Odia and English. ETV Bharat is the latest initiative of the five-decade old multi-dimensional Ramoji Group. The Group's highly successful media endeavors include : Eenadu - one of the largely circulated language dailies in the country , and ETV Network with Telugu general entertainment, infotainment and news channels. With a strong lineage of the most trusted media house, ETV Bharat would draw on its strengths of decades' long experience and innovation. ETV Bharat will combine the new technologies of mobile and digital media to engage news and information seekers in a new connected world. It will be driven by well-established news gathering setup, technology specialists and other professionals.

Recorded February 12, 2021Current Episodes at https://walkinverse.buzzsprout.com/I am moving all podcast here slowly. I will keep buzzsprout for all public reports and here for member only content.Report #37, "Gates, Fauci, and Operation Warp Speed: It's All About Connections." In the last report, we reviewed the mRNA experimental injectable technology. Now we will show a few connections behind it. Grab a pen and notebook and enjoy the report.In the last report, we reviewed the mRNA experimental injectable technology. Now we will show a few connections behind it.To date, health officials claim the novel COVID-19 soars past 16.2 million cases for a virus with a 99.9% survival rate. To justify case count, they continue to use a test proven to produce false positives. This immoral act allows for compliance through fear as these elites can accelerate their agenda without resistance.But before we dig further, please hear these words and wipe the dread from your mind. We will prevail once we remove our eyes from man and place them on the Almighty.And as stated in Isaiah 35:3-5, we have nothing to fear.“Strengthen the weak hands, And make firm the feeble knees. 4 Say to those who are fearful-hearted, “Be strong, do not fear! Behold, your God will come with vengeance, With the recompense of God; He will come and save you.” 5 Then the eyes of the blind shall be opened, And the ears of the deaf shall be unstopped.”Isa 35:3-5With those words in mind, let's view the network which drives the mRNA agenda.Many question why government officials and healthcare providers push an experimental genome therapy labeled a vaccine. They realize it causes illness and death. They have no discernment of long or short-term side effects. And yet, the answer lies before us. Massive financial gain and control for continuous revenue streams at our expense.In an interview, Bill Gates boasted how the vaccine industry returned a 20-1 investment. This statement shows how these elites play for keeps. They do not have our well-being in mind (1).And soon, a Gates-backed (2) firm will release 200 million vaccine kits and millions of experimental injections for vaccination against a coronavirus, aka a common cold.Back in May, Korea's S.K. Bioscience pharmaceutical company received $3.6 million in research funds from the Gates Foundation to support the development of a COVID-19 vax. This same company works as a contract manufacturer for AstraZeneca, which received $750 million from CEPI and GAVI (3) back in June 2020 to support the manufacturing, procurement, and distribution of mRNA injectable technology. In addition, AstraZeneca agreed to supply 1-Billion doses to low and mid-income nations. On top of these quantities, they announced a supply of 400 million doses ready for the E.U. And all the while, under the cover of night, the Imperial College steps into the vaccine game. They plan on another variation by the first half of 2021. Will it work? They have no clue. Professor Robin Shattock (4), the head of the vaccine development team at the University of Imperial College, stated, “We anticipate if everything goes really well, that we'll get an answer as to whether it works by early next year.”Professor Shattock is from the same Imperial College where Neil Ferguson used his fraudulent models to lock the world down (5) through data manipulation. He used invalid inputs based on early estimates. He selected outdated demographics, populations, and hospital bed counts to inflate numbers artificially. Instead of data from specific states to gather credible metrics, his models used the entire U.S. to drive COVID-19 spread. This skyrocketed infection rates and fears, as the model assumed everyone spreads the disease at the same rate—for virus spread detection, it's an outright scam and a crime against humanity. Yet, he still roams free without consequence. Why?The answer lies in the secure funds received from the European Commission, Bill and Melinda Gates Foundation, Wellcome Trust, MRC, and the NIH (Anthony Fauci), which indicates the degree of corruption imposed upon humanity for long term profits.And when we look to NIH and Fauci, we witness extended deception with their ties to Moderna (6). With the mRNA-1273 experiment, the U.S. government appears to have joint ownership through filed patents. With $472 million secured, Moderna plans to reach its target of 500 million doses per year, with a ramp-up to one billion in 2021. Also, (7) DARPA joins Moderna to develop an implantable biochip for the deployment of experimental therapies, which can affect human DNA.But at (8) $19.50 per dose, subsidized by taxpayers, does it matter? It's all about people over profits, which circles us back to GAVI, the WHO, CEPI, and Trump's Operation Warp Speed.Trump pulled finances (9) from the WHO, which everyone cheered as he handed it over to GAVI, the Vaccine Alliance. What most may not realize, Gates and his foundation founded GAVI in 2000 (10). So when Trump pledged $1.16 billion at the virtual Global Vaccine summit, this became part of the Fiscal budget for 2020-2023, which solidified the fact he did not have the American people's best interest in mind. Instead, he increased the hold Bill Gates has on the U.S. population and their health.At the summit, Gates stated, “Since its inception GAVI has helped vaccinate more than three-quarters of a billion children … And now, it's stepping up and saying it's willing to deliver a COVID-19 vaccine as soon as one is available to end the pandemic as soon as possible, … We must also renew our commitment to delivering every life-saving vaccine there is to every child on earth.”In addition, GAVI received a donation of $5 million from the Rockefeller Foundation for “routine immunization programs” and “play a major role in the rollout of a future COVID-19 vaccine.” which aligns with their playbook, Operation Lockstep (11).On top of this, who did Trump put at the helm of Operation Warp Speed? Another Gates connection, a former executive of GlaxoSmithKline, Moncef Slaoui. His role? Work hand in hand with General Gustave Perna for the production and vaccination across the United States.Now we'll look at CEPI, Operation Warp Speed, and Novavax. In 2017 Gates co-founded, “The Coalition for Epidemic Preparedness Innovations (CEPI)” (12) to stop epidemics via vaccines. It's the largest vaccine charity in the world. They made their mark across mainstream when they granted $388 million to an unknown biotech company, Novavax. Another company to fill the world with mRNA injections for COVID-19 (Certificate of Vaccine Identification – Artificial [1] Intelligence [9]). In a move that baffled many, Operation Warp Speed (12) also selected this company and awarded them $1.6 billion in taxpayers' funds. So while the people of the United States have their rights revoked and business destroyed at astronomical rates, the Trump administration gave your future away to Gates for an injection never used or tested on humans.And all the while, the media, Fauci, Gates, social media companies, politicians, and others lied outright to the people about HCQ (13). They knew it worked from day one. But as we see from facts, Big Pharma revenue streams and kickbacks outweighed our health.Instead of protecting people's lives, our officials schemed with these monsters behind closed doors to push an experiment to alter your DNA (14). As learned in Professor Klungland's research, “RNA has a direct effect on DNA stability.” He notes how several research groups collaborate to understand the effects this can have on the DNA molecule. He stated, “We already know that R-loop areas are associated with sequences of DNA containing active genes and that this can lead to chromosomal breakage and the loss of genetic information…” This reveals absolute modification, regardless of what the fake fact-checkers, mainstream, social media channels, or Fauci's pundits claim.To drive this point one step further, we look to the National Cancer Institute for clarification (15). Through research, they learned modification in human mRNA affects gene expression, “NAT10, an enzyme, was found to be responsible for the modification, which itself has been implicated in cancer and aging. This is one of the first examples of a unique chemical modification to mRNA…”To date, these companies refuse doctors and researchers the information required to learn the effects these synthetic drugs have on the human body. But it looks like another revenue stream in cancer therapies with the chemical modification seen in these experiments.And while the PREP Act combined with the unlawful classification of mRNA as a vaccine, these corporations have 100% immunity from all legal action (8) while they engage in an experiment without the people's informed consent (16) — a process which requires compliance or rejection of a medical procedure such as surgeries, anesthesia, radiation, chemotherapy, vaccination, and other scenarios.These experimental war crimes continue under the guise of trials (17), “A new vaccine trial is underway in the U.K. to test whether mixing and matching different COVID-19 vaccines for the first and second doses is effective,” they continue, “The country is currently using the Pfizer-BioNTech vaccine and Oxford-AstraZeneca vaccine, which both require two doses. For the study, run by the National Immunization Schedule Evaluation Consortium, patients will get one dose of each.”Remember, they never approved mRNA technologies for human use. These professionals for profit don't know or care about the long or short term side effects. To further prove these drugs still exist in the experimental stage, Moderna started on July 27, 2020, and will end on October 27, 2020, as noted by the study (18), “A Study to Evaluate Efficacy, Safety, and Immunogenicity of mRNA-1273 Vaccine in Adults Aged 18 Years and Older to Prevent COVID-19.” Pfizer (19) began their test on humanity on April 29, 2020, with a target primary completion on August 3, 2021, and the experiment to end on January 21, 2023, as noted in the “Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals.”With each injection, they test their poisons on an ill-informed public. And due to PREP, if you or your loved one becomes injured or dies from these jabs, you have zero recourse. Without informed consent, all involved in administration, production, delivery, and procurement—guilty of war crimes against humanity as stated in the Nuremberg Code (20), “The voluntary consent of the human subject is absolutely essential.” No bribes or coercion—all the facts known beforehand. For those front line workers, LEO, Military, Politicians who follow orders, no excuse. During the trials of Nuremberg, ignorance did not afford reprieve from the consequences of their willful actions. They knew and still tested on humans without consent (21).“THE PROOF AS TO WAR CRIMES AND CRIMES AGAINST HUMANITYJudged by any standard of proof the record clearly shows the commission of war crimes and crimes against humanity substantially as alleged in counts two and three of the indictment. Beginning with the outbreak of World War II criminal medical experiments on non-German nationals, both prisoners of war and civilians, including Jews and “asocial” persons, were carried out on a large scale in Germany and the occupied countries. These experiments were not the isolated and casual acts of individual doctors and scientists working solely on their own responsibility, but were the product of coordinated policy-making and planning at high governmental, military, and Nazi Party levels, conducted as an integral part of the total war effort. They were ordered, sanctioned, permitted, or approved by persons in positions of authority who under all principles of law were under the duty to know about these things and to take steps to terminate or prevent them.”Sounds familiar?When Governments (8) and officials receive kickbacks and taxpayers fund Big Pharma experiments with no legal ramifications, it no longer about one health. It's all profits.The time's at hand to end this experiment, or they will end us—no more compliance.There are more of us than them.References* Freedom Lovers TV. 2020. Bill Gates Confesses Vaccines Are His Best Investment w/ ROI of 20 to 1.* Soo Kim. 2020. “Coronavirus Vaccine Update as Bill Gates-Backed Firm Could Make 200 Million Kits a Year.” Newsweek, July 27, 2020, sec. News.* Staff. 2020. “AZD1222 SARS-CoV-2 Vaccine.” Precision Vax. December 6, 2020.* Imperial College. n.d. “Professor Robin Shattock.”* Osburn, Madeline. 2020. “Inaccurate Virus Models Are Panicking Officials Into Ill-Advised Lockdowns.” The Federalist. March 25, 2020.* Patrick Howley. 2020. “BUSTED: NIH Owns Financial Stake In Gates-Funded Coronavirus Vaccine.” National File (blog). June 29, 2020.* Franz Walker. 2020. “DARPA Funded Implantable Biochip Can Potentially Be Used to Deploy Moderna's MRNA Vaccine.” Nanotechnology News. October 12, 2020.* Apuzzo, Matt, and Selam Gebrekidan. 2021. “Governments Sign Secret Vaccine Deals. Here's What They Hide.” The New York Times, January 28, 2021, sec. World.* Broze, Derrick. 2020. “Vaccine Bait & Switch: As Millions Pulled From WHO, Trump Gives Billions To Gates-Founded GAVI.” The Last American Vagabond (blog). July 7, 2020.* The Bill & Melinda Gates Foundation [Internet]. [cited 2021 Feb 9]. Available from: https://www.gavi.org/investing-gavi/funding/donor-profiles/bill-melinda-gates-foundation* N/A. Operation Lockstep: From The Rockefeller Playbook [Internet]. Shadaily. 2020 [cited 2020 Dec 7].* Carmichael, Taylor. 2020. “Why Was Novavax Awarded Almost $2 Billion in Free Money?” The Motley Fool. July 22, 2020.* Patrick Howley. 2020. “EXPOSED: The Truth About Fauci and Birx, Bill Gates And Globalist Elites.” National File. March 26, 2020.* Eyrun Thune. 2020. “Modified RNA Has a Direct Effect on DNA.” PHYS.ORG. January 29, 2020.* NIH. 2018. “A Novel MRNA Modification May Impact the Human Genetic Code.” Center for Cancer Research. November 15, 2018.* Kirsten Nunez. 2019. “Informed Consent in Healthcare: What It Is and Why It's Needed.” Healthline. October 11, 2019.* O'Kane, Caitlin. 2021. “U.K. Study Will Test If Getting Doses of Two Different COVID-19 Vaccines Is Effective.” CBS News. February 4, 2021.* ModernaTX, Inc. 2020. “A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of MRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older.” Clinical trial registration NCT04470427. clinicaltrials.gov.* BioNTech SE. 2021. “Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals.” Clinicaltrials.Gov. February 9, 2021.* Government. 2020. “THE NUREMBERG CODE.” February 16, 2020.* Government. 1949. “TRIALS  OF WAR CRIMINALS  BEFORE THE  NUERNBERG MILITARY TRIBUNALS  UNDER  CONTROL  COUNCIL LAW No. 1.” 1949. This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit walkinverse.substack.com/subscribe

檀香们，周五好，欢迎收听本期檀谈，欢迎观看《檀谈牛熊交易所》完整版视频内容，购买链接：http://xima.tv/VQvxJ2?_sonic=02021年1月27日，欧盟突发利空：德国联邦经济和能源部公布了年度经济报告，将2021年的经济增速预期从4.4%下调至3%。去年九月德国政府预期经济会在2022年初恢复到疫情前水平，现在复苏的时间延迟到了 2022年年中。德国是欧盟的火车头，牵一发动全身，欧盟官员随后表示，市场严重低估了欧盟进一步降息的可能性。言外之意，经济不及预期，所以还要放水，打压欧元汇率。消息一出，全球资本市场反应剧烈。1月27日，德国股市盘中最大跌幅2.8%，收盘跌1.8%。开盘较晚的美股三大指数跌幅均超过2%。28日开盘，亚太股市也是一片绿油油。我们的创业板更是跌了3.6%。变异毒株频发，德国考虑“封国” 为什么恐慌？这要从德国下调增长目标的背后原因说起。1月18日，德国巴伐利亚州发现了一例新冠病毒变异毒株，并且该变异毒株与目前全球所知的任何变异毒株都有所不同。种种迹象表明，德国发现的这个新病毒株，可能不简单。目前，德国政府派出了相关权威研究所对该变异毒株进行了进一步分析，并且加强对德国境内的新冠病毒测序以及分析等工作，从而更好的监测新冠病毒变异的趋势。祸不单行，1月26日巴伐利亚州又报告了新毒株。中新社柏林1月26日电 ，巴伐利亚州多名医院员工疑似感染新冠病毒变异毒株，医院已经暂时关闭。政府甚至考虑停飞国际航班。两家共有13名员工疑似感染了疑似英国的高传染性变异毒株。但到底是不是英国毒株，还不确定，基因测序仍在进行中。目前，两家医院已停止接收病人，超过3000名员工进入隔离状态。几天之内，多地报告不同类型的变异毒株，形势严峻！德国内政部长泽霍费尔当天向德国《图片报》表示，新冠病毒变异带来的风险“要求我们研究采取严厉的措施，并在联邦政府内进行讨论”。泽霍费尔并未给出上述措施出台的时间表。按照德国联邦与州一级政府协商防疫政策的议事日程，默克尔预计将于2月初再次与各州州长举行会谈，商讨下一步防疫政策走向。在一天后的27日，德国经济和能源部发布的最新报告里大幅调低经济增长预期，很有可能是临时修改。巧合的是，1月20日，我们卫健委的官员表示要返乡过年要做核酸检测，并要求各地做好快速响应准备。卫健委的这个表态也比较突然，引发不少人的抵触和吐槽。但现在看，可能是事出有因。英国毒株带来的麻烦还没解决，德国又发现新毒株。大家辛苦了一年，不能功亏一篑，所以吐槽归吐槽，大家冷静下来还是能够理解的。 疫苗被英美卡脖子，欧盟经济复苏延后德国和欧盟之所以如此谨慎，还有一个痛处——疫苗接种进度落后于英美。下面这张图是全球疫苗接种进度的Top 10。在绝对数量上，美国和中国不相上下。德国排在第六，但绝对数量只有中美的十分之一左右。比较尴尬的是，作为全世界最发达的经济体之一，欧盟的几个大国：德国、法国、西班牙、意大利都没有排进前十。多少让人有些意外。 目前全世界疫苗产能主要掌握在辉瑞和中国手里，辉瑞是美国公司。我们在之前一篇文章中提过，目前的世界格局，可以按照语言来划分，英语国家基本上是一个阵营。接种数量排前五的国家中，美国第一，昔日的宗主国英国排在第三；以色列第四，接种数量接近500万，但以色列总人口只有900万，所以接种比例排在第一，难怪阴谋论者总说犹太人控制着美国；第五的阿联酋是跟中国合作的，接种比例排名世界第二，阿联酋除了自己接种外，还向周边国家“赠送”疫苗。按照阿联酋外交部发言人的最新通报，该国目前的新冠疫苗接种率（26%）位居世界第二（仅次于以色列），疫苗人均可及率世界第五，已有超过256万人接种（大部分接种的是中国疫苗）。计划三月底前让一半国民接种。美国CNBC称，去年9月，这个地处沙漠的小酋长国先让身处一线的医务工作者和政府官员接种中国国药集团的疫苗，到了去年底则开始为全国民众接种疫苗。大家不要觉得阿联酋占了中国便宜，事情是这样的：因为我们国内疫情控制较好，所以找不到足够多的三期临床对象，必须跟其他国家合作。阿联酋是愿意配合中国的国家之一。在西方不断就疫情起源和疫苗安全性质疑中国的情况下，去年6月国药集团新冠灭活疫苗国际临床试验（Ⅲ期）在阿布扎比举行启动仪式。9月，阿政府批准中国疫苗紧急使用，12月，这款疫苗在阿获批上市。尽管一些外媒质疑相关试验数据，但阿联酋依然按计划展开大规模接种。这些国家信任中国，我们自然也要投桃报李，优先供应一部分，合情合理。 欧洲当时不相信中国疫苗，还不断责难中国，现在美国人掌控着第一批疫苗产能，但欧洲并不在优先分配的名单上，可以说欧洲这波操作是赔了夫人又折兵。更惨的是，不但没有优先分配，甚至比承诺的还要少。1月15日，美国辉瑞公司发表公告称，由于需要对比利时工厂进行“生产流程的调整”，在接下来3至4周内给欧盟国家的新冠疫苗交付量将受到影响。英国阿斯利康公司也表示，由于一座疫苗工厂产能不足，该公司在 3月底前只能向欧盟提供3100万剂疫苗，较之前承诺的8000万支少了 60%多。对此，欧盟委员会表示“不可接受”，多个国家表示要起诉辉瑞。在疫苗供应上，欧盟被英国和美国摆了一道。疫苗接种滞后的结果就是，欧盟依然不敢放开社交管制，线下经济半停摆，还要给餐饮业这些受冲击的行业发放大额补贴。变异毒株会影响疫苗效果吗？如今全球确诊超过一亿大关。大家把希望都寄托在了疫苗上。那么变异毒株到底会不会影响疫苗效果？来看看权威机构的说法。1月27日，辉瑞和BioNTech公布了实验研究结果。结果显示，疫苗对发现于英国和南非的变异毒株产生中和反应。但对同时存在对南非突变变体的中和反应水平较低。对此，辉瑞和BioNTech SE表示，研究结果中的微小差异不太可能导致疫苗有效性的显著降低，这些发现并不意味着需要开发新的疫苗来应对，但如果变异毒株出现逃逸免疫反应，公司将会做好应对准备。国药集团中国生物董事长杨晓明表示，在研发过程中，研究人员已经对不同地区来源的各种变异毒株，进行了实验，对I、II期临床试验志愿者免疫以后的血清，也做了综合实验。有明确数据表明，疫苗对各种变异株都有预防作用。灭活疫苗免疫以后，对包括英国突变的毒株和以往全球分离到的大概八九株的不同的变异株都有中和效果。从辉瑞和国药的表态中，我们可以看出，疫苗对某些毒株的效果可能会打一点折扣，但没有到失效的程度。需要不需要重新研发，辉瑞也没把话说死。但目前来看，疫苗还是有效的。主要的问题还是在产能和分配上。除了疫苗，还有之前提到过的玻璃瓶，以及配套的仓储物流设备。截止2021年1月10日，辉瑞已运送了3290万剂新冠疫苗。按公司原计划，到2020年底前，将运送5000万剂疫苗，实际交付远不及预期，主要是因为存储环节现在还跟不上。全球的产能到底够不够用呢？辉瑞2021年的产能足够支撑全球10亿人使用，其中有一亿剂将卖给中国的复星医药。但主要的产能要在2月底才能投入生产，产能爬坡也需要时间。另一家大厂Moderna预计到2021年将提供6亿剂至10亿剂疫苗。阿斯利康之前表示2021年产能30亿剂，但从现在的交付情况看，这个数据可信度很低。国药中生2021年计划生产10亿剂，够五亿人使用，自给自足问题不大。科兴一期已经完成了年产5亿支的疫苗建设，并且投入了正式的生产。二期5亿支生产线正在验收当中，预计2月份可以投入生产。加起来也是10亿支产能。全球来看，已经进入量产阶段的公司，产能建设基本在二月底完成，也就是一个月之后。后面就看相关的原材料能不能跟上。中国前期获批进入临床阶段的七个新冠疫苗项目，全部用了德国肖特的中硼硅药用玻璃，没有一家采用国产药玻。全球中硼硅玻璃管巨头企业主要有3家，分别是德国肖特SCHOTT、美国康宁CORNING和日本电气硝子NEG。肖特一家占50%产能。在中硼硅玻璃紧缺的背景下，也有相关公司正在冲刺IPO。2020年10月28日，凯盛君恒宣布疫苗用玻璃管成功上线，启动科创板上市计划。这家公司是中国建材集团旗下控股孙公司，公司致力于中硼硅玻璃管的研发和生产。从肖特公司的公开表态来看，产能紧缺没有到致命的程度，也不限制向中国的供应。2020年7月30日，肖特宣布，公司提供的中硼硅玻璃可制成多达20亿剂疫苗药瓶包装，肖特与全球大型医药公司达成合作协议并立即生效，首批药瓶将交付给中国及海外医药公司。此外，肖特还会在全新药玻工厂再新增产量4万吨，约可制成70亿包装容器。《科创板日报》的记者曾经采访过肖特中国区市场部负责，这位负责人表示肖特已经在为全世界3/4的新冠疫苗项目供应药瓶。所以大家可以放心，最多再熬两个月，全世界疫苗接种将进入加速期。虽然这个进程落后于之前的预期，但不影响大局。经济复苏，尤其是线下经济的复苏会延迟，投资上的布局也要相应调整。受德国调低预期和欧洲央行降息信号的影响，资本市场会有波动，但各国央行大概率要继续放水，进行对冲。全球经济真正开始复苏，恐怕要等到三季度末，像电影院、旅游业、国际航班这些才可能进一步放开。大家可以在首页搜索《檀谈之牛熊交易所》，观看视频。

The UK today became the first country to approve the Covid-19 vaccine developed by Pfizer Inc and its German partner BioNTech SE. Tune in to this episode as Rohini & Sachin discuss the Pfizer's covid vaccine, first in the world.

UTILIDADES PARA TRADERS AQUÍ >> https://linktr.ee/inversionesytrading Pre-Mercado Americano – Destacados: La Bolsa Americana cae a pesar del anuncio de Pfizer-BioNtech, donde confirman que el Reino Unido aprobó su uso. Los inventarios del API subieron inesperadamente, gatillando una presión bajista en el Petróleo WTI. El Oro logra retomar la senda alcista y se posiciona sobre los $1800 ante nuevas conversaciones de estímulos en EEUU. Recuerda seguirnos en nuestro Canal de Youtube para acceder a nuestras Transmisiones en Vivo donde cubrimos eventos de alto impacto en los mercados. https://www.youtube.com/inversionesytrading Informe de Pre-Mercado Americano: Hoy, en el pre-mercado la Bolsa Americana retrocede y se acopla a las caídas en la Bolsa Europea. El Euro Stoxx cae -0.35%, el DAX -0.39%, el FTSE -0.03% y el Ibex 35 es el único que logra recuperar el terreno alcista al subir +0.13%. La tasa de desempleo en la Zona Euro se publicó en 8.4% y el Índice de Precios al Productor mejoró al publicarse en -2.0%. A esto tenemos que añadir el anuncio de PFizer-BioNTech. La vacuna contra el coronavirus desarrollada por Pfizer Inc. y BioNTech SE estará disponible en el Reino Unido a partir de la próxima semana después de que la vacuna haya recibido la autorización de emergencia. El país ha ordenado suficientes dosis de la vacuna para inmunizar a 20 millones de sus 67 millones de habitantes, siendo los muy ancianos y los que están en hogares de cuidado los primeros en la línea de vacunación. La Administración de Alimentos y Drogas de EE.UU. se reúne el 10 de diciembre para discutir la aprobación del tratamiento de Pfizer. Por ahora, la pandemia continúa cobrando su cuota con muertes en Alemania que alcanzan un máximo de siete meses y con un aumento de las hospitalizaciones en los EE.UU. A pesar de estas noticias, las caídas se sienten en ambas Bolsas. Una de las principales razones que se atribuyen al retroceso que estamos viendo ahora es la toma de ganancias de algunos inversionistas luego del 14% del movimiento alcista visto en el mes de noviembre, lo que hace sentido. Por otro lado, también conocimos que Joe Biden dejaría en vigor el acuerdo comercial de la primera fase mientras lleva a cabo una revisión completa de la política de Estados Unidos hacia China. Esto podría no apaciguar las relaciones entre ambas naciones. #forex #inversiones #trading #trader #dolar #dinero #spx #sp500 #nasdaq #dowjones #wallstreet #stocks #acciones #inversion #indices #oil #petroleo #delta #trump #covid #europa #acciones #money #daytrading #FOREXENVIVO #FOREXTRADING #DAYTRADING #AIE #BITCOIN #PFIZER #VACUNA #UK #FDA #COVID #BTC #Ripple $XRP $BTC $ETH #Criptomonedas

GBP/USD was trading above 1.3400 going into European trading, having hit three-month highs at 1.3440 amid broad-based US dollar weakness. However, the pair dropped back to 1.3350 after the Medicines and Healthcare Products Regulatory Agency (MHRA), the UK's medical regulator, gave a green signal to the coronavirus vaccine co-developed by BioNTech SE and Pfizer Inc on Wednesday, concluding it's both safe and effective. The cable traders seems to be waiting for news from the Brexit negotiations for new imputes. The vaccine approval news failed to boost risk appetite, which is nowhere near the support came from the vaccine efficacy news in November. EUR/USD has cleared the 1.2014 August peak, such a move targets initially 1.2145, the 78.6% retracement and longer term 1.2622, the 200 month moving average. The dollar weakened in early European trade Wednesday, as vaccine optimism and talk of further fiscal stimulus from the United States gave fresh encouragement to higher-yielding currencies. The dollar index was down 0.2% at 91.157, hitting its lowest levels since April 2018. USD/JPY rose 0.2% to 104.47, while the risk-sensitive AUD/USD climbed 0.2% to 0.7381.

UTILIDADES PARA TRADERS AQUÍ >> https://linktr.ee/inversionesytrading Pre-Mercado Americano – Destacados: La Bolsa Americana sube luego del anuncio de Pfizer-BioNTech de buscar la aprobación de su vacuna. El petróleo WTI sube +0.42% a pesar de no tener avances tras la reunión de la OPEP+. El Bitcoin logró cerrar la vela mensual sobre los 19.500 usd. Hoy detiene las alzas y cae -4%. Recuerda seguirnos en nuestro Canal de Youtube para acceder a nuestras Transmisiones en Vivo donde cubrimos eventos de alto impacto en los mercados. https://www.youtube.com/inversionesytrading Informe de Pre-Mercado Americano: Hoy, en el pre-mercado la Bolsa Americana parte este último mes de trading con el pie derecho, acoplándose del optimismo visto en la Bolsa Europea tras el anuncio de Pfizer y BioNTech. Pfizer Inc. y su socio BioNTech SE buscaron la autorización reglamentaria para su vacuna Covid-19 en Europa, siguiendo un movimiento similar de Moderna Inc. ayer. Esto pone a las vacunas en camino para su aprobación antes de fin de año. El vicepresidente Mike Pence señaló una rápida respuesta de los reguladores de EE.UU., diciendo que la distribución de una vacuna podría comenzar ya en la tercera semana de diciembre. Por otra parte, hay nuevas pruebas de que el Covid-19 estaba en los EE.UU. antes de lo que se había reconocido anteriormente con un estudio que encontró infecciones en muestras de sangre recogidas a finales de 2019. En la Bolsa Europea el Euro Stoxx sube +1.01%, el DAX +1.05%, el Ibex +0.94% y el FSTE +2.17%. Por otro lado, hemos conocido que la reunión de la OPEP no ha concluído nada. A pesar de la reunión de ministros celebrada el domingo y de la reunión de los miembros de la OPEP celebrada ayer, todavía no hay consenso entre los miembros del cártel y sus aliados sobre los niveles de producción una vez que expiren los actuales frenos en enero. Esto ha significado que la reunión de la OPEP+ prevista para hoy para ultimar un acuerdo se ha pospuesto hasta el jueves para dar más tiempo a encontrar un compromiso. Aunque el mercado del crudo no es ajeno a las largas y difíciles reuniones de la OPEP, el punto muerto está inquietando a los comerciantes, ya que el petróleo tiene otra sesión volátil hoy, ya que los futuros oscilan entre las ganancias y las pérdidas #forex #inversiones #trading #trader #dolar #dinero #spx #sp500 #nasdaq #dowjones #wallstreet #stocks #acciones #inversion #indices #oil #petroleo #delta #trump #covid #europa #acciones #money #daytrading #FOREXENVIVO #FOREXTRADING #DAYTRADING #AIE #BITCOIN #PFIZER #VACUNA #UK #FDA #COVID #BTC #Ripple $XRP $BTC $ETH #Criptomonedas

Bolsa Europea opera mixta mientras la Bolsa Americana avanza ante posibles nuevos estímulos viernes, 20 noviembre, 2020 7:32 am GMT-0500 La Bolsa Americana opera al alza tras reanudación de conversaciones de estímulos en EEUU. La Bolsa Europea opera en territorio mixto ante incertidumbre por el Brexit. El barril de petróleo logra quebrar los $42 usd/barril ante posible vacunación temprana a la población mundial. Recuerda seguirnos en nuestro Canal de Youtube para acceder a nuestras Transmisiones en Vivo donde cubrimos eventos de alto impacto en los mercados. https://www.youtube.com/inversionesytrading Informe de Pre-Mercado Americano: Hoy, en el pre-mercado la Bolsa Americana se encuentra operando al alza a raíz de la reanudación de las conversaciones del paquete de estímulos en el Senado de EEUU. Esto logró calmar las aguas luego de la confrontación entre el Secretario del Tesoro y el presidente de la Fed. Un desacuerdo ha surgido entre el Secretario del Tesoro Steven Mnuchin y el Presidente de la Reserva Federal Jerome Powell sobre si preservar los programas de préstamos de emergencia diseñados para apuntalar la economía. Mnuchin escribió a la Reserva Federal exigiendo la devolución del dinero que el gobierno provee al banco central para prestar a ciertos mercados. La Reserva Federal emitió un comunicado diciendo que el «conjunto completo» de medidas debe mantenerse. Aunque Mnuchin dijo que sólo está cumpliendo con la ley prescrita por la Ley de Atención al Cliente, los mercados reaccionaron con nerviosismo ante las señales de desacuerdo entre los dos principales responsables de la política económica de los Estados Unidos. A pesar de esto y gracias a declaraciones del líder demócrata del Senado, los mercados lograron calmarse. ¿Qué dijo? El líder de la minoría demócrata en el Senado, Chuck Schumer, dijo que el líder de la mayoría republicana, Mitch McConnell, acordó revivir las negociaciones para elaborar un nuevo paquete de alivio fiscal. A esto, tenemos que sumar el optimismo de una posible vacunación temprana de la población. La Unión Europea podría pagar más de 10.000 millones de dólares para comprar dosis de la vacuna de Pfizer Inc. y BioNTech SE, ya que el bloque se mueve para aprobar las inyecciones tan pronto como la segunda mitad del próximo mes. EEUU podría seguir a la Unión Europea, ya que las hospitalizaciones estadounidenses alcanzaron un récord cercano a las 80.000, ya que el sistema médico del país está bajo presión por el aumento de la pandemia. California impuso un toque de queda a las 10:00 p.m. a la gran mayoría de los residentes. Por otro lado, tenemos el nulo avance de las conversaciones del Brexit entre el Reino Unido y la Unión Europea, lo que genera incertidumbre y no le permite el avance a los índices europeos que hoy operan mixtos. El EuroStoxx sube +0.58% pero el Dax Alemán cae -0.03%. Por otro lado, el Ibex logra mantener las alzas al avanzar +0.08% mientra que el FTSE 100 cae -0.13%.

Following the good, early news from Pfizer's COVID-19 vaccine, Ticketmaster is said to be deep in planning for a post-COVID concerts restart. Earlier this week, Pfizer, producers of Viagra, said a vaccine it had been developing with German partner BioNTech SE was 90% effective against COVID-19, based on large-scale studies. The medical community is cautiously optimistic, and Australia's Government has pounced with a deal to nab 10 million doses, which will cover five million people based on the two required doses. Live Nation's ticketing subsidiary is reportedly building a framework for a safe return to touring, by leveraging smart-phone technology and science. The in-development project pulls the levers on the Ticketmaster digital ticket app, third party health information companies and vaccine distribution providers. After buying a ticket for the show, the punter would need to verify that they've been vaccinated or test negative for the novel coronavirus within a specific timeframe. Once given the green light, that information would be passed along a digital chain and made available to the concert-goer. Ticketmaster President Mark Yovich said “We're already seeing many third-party health care providers prepare to handle the vetting — whether that is getting a vaccine, taking a test, or other methods of review and approval – which could then be linked via a digital ticket so everyone entering the event is verified. “Ticketmaster's goal is to provide enough flexibility and options that venues and fans have multiple paths to return to events, and is working to create integrations to our API and leading digital ticketing technology as we will look to tap into the top solutions based on what's green-lit by officials and desired by clients.” It has been reported that a decision on whether to require proof of vaccination would sit with the event organiser, not with Ticketmaster. With close to zero income flowing into its coffers for months, Live Nation and Ticketmaster, the leading players in the space, are totally exposed to the pandemic. Since March, the touring titan has tested the waters for COVID-safe productions, which have included socially-distanced shows and drive-in concerts. In recent months, LN announced a Global Relief Fund had raised US$15 million, to support 15,000 roadies, techs and all the backstage crew now out of work due to the pandemic.

Siboniso highlights the positive activity on the JSE yesterday, buoyed by the announcement of a 90% effective vaccine from Pfizer and BioNTech SE, which saw significant gains from sectors such as oil, retailers and financials.

US equity markets soared after biotechnology companies Pfizer Inc (up +7.69%) and BioNTech SE (13.91%) announced that their COVID-19 vaccine candidate achieved "success" in the first interim analysis of a Phase 3 study. - Dow jumped +835-points or +2.95% to 29,157.97, logging its biggest one day climb since 5 June. The Dow hit an all-time high earlier in the session, surging more than >1,600-points or ~5.7% to 29,933.83. American Express Co rallied +21.39%, Boeing Co +13.7%, JPMorgan Chase +13.5% and Walt Disney Company +11.9%. The broader S&P500 +1.17% to 3,550 and also touched a record intra-day high. The Energy sector (up +14.22%) led seven of the eleven primary sectors higher, while Consumer Discretionary (down -1.59%) and Information Technology (0.73%) underperformed. Companies likely to benefit from a re-opening of the economy prospered on the vaccine news, with airlines (United Airlines Holdings Inc up +19.15%, American Airlines Group Inc +15.18%, Southwest Airlines Co +9.70%) and cruise lines (Royal Caribbean Cruises Ltd up +28.79% and Carnival Corp +39.29%) The technology-centric Nasdaq fell -1.53%, with the so-called ‘stay-at-home' stocks struggling. The Nasdaq-100 index - composed off the 100 biggest components of the Nasdaq Composite – fell -2.2% and snapping a five-session win streak. Zoom Video Communications Inc tumbled -17.37%, Netflix Inc -8.59% and Amazon.com Inc -5.06%. The small capitalisation Russell 2000 index gained +3.7%.

Wikifolio-Trader Roland Weis (Can Slim https://www.wikifolio.com/de/de/w/wfaktikult): "Meine größte Position ist Paion. Die mussten an ihrem Präparat Remimazolam noch arbeiten. Die haben die Zulassung nun für Japan. Auch aus den USA von der FDA ist die Freigabe gekommen, kurz darauf auch aus China. In Europa steht es noch aus. Remimazolam ist ein Narkosemittel. Das normale Narkosemittel ist Propofol und genau das war jetzt in der Corona-Krise knapp. Paion ist der heimliche Gewinner, der heimliche Star. - Magforce war einer der Aktien, die sich nicht erholt haben, obwohl es eine Pharmafirma ist." Zudem besprochene Aktien aus dem wikifolio.com: SARTORIUS AG, BIONTECH SE, EVOTEC SE.

US equity markets advanced, getting a boost in the final hour of trading after CNBC reported that the Republican party are considering extending the enhanced unemployment insurance benefit albeit at a dramatically reduced level of US$400 per month (down from US$600) through the rest of the year - Dow up +165-points or +0.62% to 27,005.84 and its highest close since 9 June. Pfizer Inc gained +5.1% and those of BioNTech SE +13.72% after the companies said they will receive US$1.95B from the U.S. government to produce at least 1M doses of their experimental COVID-19 vaccine if it receives approval or emergency use authorization from the Food and Drug Administration (FDA). The broader S&P500 advanced for a fourth straight session, up +0.57% . NASDAQ edged +0.22% higher. Advanced Micro Devices rose +8.4% to settle at an all-time high (US$61.79). In merger and acquisition (M&A) headlines, Dell Technologies Inc (up +1.15%) is exploring options for its $50 billion stake in cloud computing company VMWare Inc (up +0.56%), according to the Wall Street Journal quoting people familiar with the matter.

More upbeat headlines around progress on coronavirus vaccines and fresh gains for technology heavyweights underpinned the the latest gains for US equity markets albeit trading volumes were light - Dow eked out a +9-point gain, recovering from an earlier -150-point decline. Dow member Pfizer Inc (up +0.69%) and BioNTech SE (+3.46%) reported early positive data on a joint coronavirus vaccine candidate, saying the drug “elicited high, dose level-dependent SARS-CoV-2-neutralizing titers and RBD-binding IgG concentrations after the second dose.” Pfizer shares rose 0.6% on the news while BioNTech traded 3.4% higher. The broader S&P500 gained +0.84% albeit Consumer Discretionary (up +3.14%), Information Technology (+2.58%) and Communications Services (+1.25%) were the only primary sectors to advance. Energy (down -1.73%) was the worst performing primary sector. Airlines were under pressure (American Airlines Group Inc down -3.69%, United Airlines Holdings Inc -4.69% and Delta Air Lines Inc -3.07%) after data from the U.S. Transportation Security Administration showed travel demand declined last week, snapping a 12-week increase. The technology-centric NASDAQ outperformed with +2.51% rally (to 10,767.09), booking its largest one-day percentage climb since 29 April and 28th record closing high of 2020. Amazon.com Inc jumped +7.93% (to US$3,196.84), with analysts at Goldman Sachs hiking their price target to US$3,800 per share and the highest among analysts covering the e-commerce giant. Analysts at MKM Partners also lifted their target price +33% to US$3,350 and citing the company as a two-pronged beneficiary of the COVID-19 pandemic given the accelerated shift to on-line shopping and towards cloud computing. The rise came after Amazon logged its worst weekly performance since the week ended 28 February - and first weekly loss in eleven weeks – last week with a -7.4% decline. Amazon is up +70.2% year-to-date. Texas Instruments Inc gained +2.01% to settle at a record closing high (US$136.58) ahead of their result tonight AEST. In merger and acquisition (M&A) news, Chevron Corp (down -2.2%) confirmed an all-stock ~US$5B deal to acquire Noble Energy Inc (up +5.44%)

A broad rally for US equity markets unravelled in the final hour of trading as fresh coronavirus concerns weighed on investor sentiment - Dow inched +10.5-points or +0.04% higher, unwinding an earlier rally of as much as +564-points or +2.2%. Dow constituent Pfizer Inc (up +4.08%) and BioNTech SE (+10.55%) rallied after the pharmaceutical groups said two of their vaccine candidates to protect against the coronavirus had received Fast Track designation status from the Food and Drug Administration (FDA). Pfizer and BioNTech said they expect to start the next phase of the vaccine trial later this month with 30,000 subjects. The companies expect to have 100M doses of a vaccine by the end of 2020 and more than 1.2B doses by the end of 2021, according to a release. The broader S&P500 fell -0.94%, having been up over >1.5% earlier in the session and briefly pushing into positive territory for the year. Utilities (down -3.62%) and Information Technology (-2.12%) led eight of the eleven primary sectors lower. Financials rose +0.32% ahead of some key results in the sector tonight AEST. The NASDAQ shed -2.13%, logging its biggest intra-day reversal since 7 April. The technology-centric index had been up as much as +1.95%. The Nasdaq-100 - which comprises the 100-largest nonfinancial companies in the composite - briefly broke above 11,000 for the first time before settling -2.2% lower. The Nasdaq 100 has only seen an intra-day reversal of that magnitude twice – the last time was 7 March, 2000. Tesla Inc settled -3.1% lower after rallying as much as 16.2% earlier in the session (and taking its market capitalisation to a record above >US$330B, ranking the electric vehicle maker as the 10th largest company in the S&P500 and more than Toyota, Ford Motor, General Motors and Fiat Chrysler Automobiles combined). Tesla's intra-day reversal was the largest swing from positive to negative since 30 June, 2010, according to Dow Jones Market Data. The 10 largest stocks in the S&P500 have an average of 1% of their float short sold – Tesla's shoer interest is almost ten times that, according to Bespoke Investment Group. Moderna Inc jumped +14.7% after Nasdaq said it was adding the drugmaker to the Nasdaq-100 Index before the market opens on 20 July. The small capitalisation Russell 2000 index fell -1.34%.